Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 1 of 84 Clinical Trial Protocol: IT001-3 10 
Study Title:  A prospective, Phase 3, randomized, multi -center, double -blind  
study of the efficacy, tolerability , and safety of oral sulopenem 
etzadroxil /probenecid versus oral amoxicillin/clavulanate  for 
treatment of uncomplicated urinary tract infections (uUTI) in 
adult women.  
Study Number:  IT001 -310 
Study Phase:  Phase [ADDRESS_324383] Name:  [CONTACT_266547] /probenecid  tablets (500 mg/500 mg)  
IND Number:  129,[ADDRESS_324384] Number  2017 -003771 -57 
Indication:  Uncomplicated urinary tract infection  
Investigators:  Multicenter  
Sponsor:  Iterum Therapeutics International Limited  
Fitzwilliam Court, 1st Floor , Leeson Close  
Dublin 2, D02 YW24  
Ireland  
Sponsor Contact:  [CONTACT_266504], MD  
Sponsor‚Äôs US Agent : Iterum Therapeutics US Limited  
[ADDRESS_324385] [ZIP_CODE]  
Medical Monitor s: Brian Murphy, MD and Phillip Cole, MD (Medpace)  
Steven I. Aronin, MD  (Sponsor) 
 
Pharmacovigilance : Medpace Clinical Safety  
Medpace SAE reporting line ‚Äì [LOCATION_002]:  
Telephone: +1 -800-730- 5779, dial 3 or [PHONE_5563]- 9911, dial 3  
Fax: +1 -866-336- 5320 or +[PHONE_5562] 
Email: medpace -[EMAIL_1925]   
    Date  
Original Draft Protocol  May 31, [ADDRESS_324386] party, with the exception of regulatory agencies and study audit personnel.  
Reproduction, modification or adaptation, in part or in total, is strictly forbidden without prior written 
approval by [CONTACT_266505] . 
 Throughout this document, symbols indicating proprietary names ( ¬Æ, ‚Ñ¢) are not displayed.  The appearance of product 
names without these symbols does not imply that these names are not protected.  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 2 of 84 SYNOPSIS  
Sponsor:  
Iterum Therapeutics International Limited  
Name [CONTACT_2756]:  
Sulopenem etzadroxil /probenecid tablets (500 mg/500 mg)  
Study Title:  
A prospective, Phase 3, randomized, multi -center, double -blind study of the efficacy, 
tolerability, and safety of oral sulopenem etzadroxil /probenecid versus oral 
amoxicillin/clavulanate for treatment of uncomplicated urinary tract infections (uUTI) in adult 
women. 
Study Number:  
IT001-310 
Study Phase:  Phase 3  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 3 of 84 Objective(s) :  
Non-inferiority Trial : 
Objective  Estimand/ Endpoint  
Primary:  
To compare  the overall response  (clinical and 
microbiologic combined response) at Day 12 
(¬±1 day)/ test of cure ( TOC ) of oral sulopenem 
etzadroxil/probenecid tablets (500 mg/500 mg) versus oral amoxicillin/clavulanate ( 875 
mg/125 mg) tablets for the treatment of 
uncomplicated urinary tract infection in adult women. Primary  Estimand : 
Endpoint of interest: Overall success 
at Day 12 (¬±1 day) /TOC  (clinical and 
microbiologic combined)  
Intercurrent events: non- susceptibility 
or resistance to amoxicillin/cla vulanate, use of rescue 
antibiotic, study discontinuation  
Population level summary of variable: 
Comparison of overall success rates 
between treatment groups  
Secondary:  Secondary  Endpoints : 
To evaluate the clinical efficacy at Day 12 
(¬±1 day) /TOC.  Clinical cure ( resolution of the 
symptoms of uUTI present at trial entry and no new uUTI symptoms) at 
Day 12 (¬±1 day) /TOC . 
To evaluate the rate of post -treatment 
asymptomatic bacteriuria at Day 12 (¬±1 day)/TOC.  Clinical cure (resolution of the 
symptoms of uUTI present at trial entry and no new uUTI symptoms)  
and microbiologic persistence ( ‚â• 10
3 
CFU/mL of the baseline uropathogen)  
at Day 12 (¬±1 day)/TOC  
To evaluate the microbiologic efficacy at Day 
12 (¬±1 day) /TOC.  Microbiologic eradi cation (<103 
CFU/mL of the baseline uropathogen) 
at Day 12 (¬±1 day) /TOC  
To further evaluate the safety profile of oral 
sulopenem etzadroxil/probenecid tablets (500 
mg/500 mg) when used for treatment of uUTI 
in adult women. Incidence of TEAEs through Day 28  
(¬±2 days) ; Changes from baseline in 
clinical laboratory tests at the Day 12 
(¬±1 day) /TOC  visit; Changes from 
baseline in vital signs at the Day 5  (+1 
day)/EOT, and Day 12 (¬±1 day) /TOC  
visits  
Additional:  Additional  Endpoints : 
To evaluate the clinical efficacy at  Day 5 (+1 
day) and Day 28 (¬±2 days).  Clinical cure ( resolution of the 
symptoms of uUTI present at trial 
entry and no new uUTI symptoms) at  
Day 5 (+1day) and Day 28 (¬±2 days).  
To evaluate the rate of post -treatment 
asymptomatic bacteriuria at  Day 5 (+1 day) 
and Day 28 (¬±2 days).  Clinical cure (resolution of the 
symptoms of uUTI present at trial entry and no new uUTI symptoms)  
and microbiologic persistence ( ‚â• 10
3 
CFU/mL of the baseline uropathogen)  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 4 of 84 at Day 5 (+1 day) and Day 28 (¬±2 
days).  
To evaluate the microbiologic efficacy at Day 
5 (+1 day) and Day 28 (¬±2 days).  Microbiologic eradi cation (<103 
CFU/mL of the baseline uropathogen) 
at Day 5 (+1 day) and Day 28 (¬±2 
days).  
To evaluate overall respon se at other relevant 
timepoints  Overall success  (clinical and 
microbiologic combined response) at 
Day 5 (+1 day) and Day 28 (¬±2 days) 
visits  
To evaluate the investigator determined 
clinical response  Investigator determined clinical 
response (clinical success, failure, and indeterminate) at Day 5 (+1 day), Day 
12 (¬±1 day)/TOC, and Day 28 (¬±2 
days)  
To evaluate overall success, clinical success, 
and microbiologic success by [CONTACT_266507], clinical success, and 
microbiologic success at Day 5 (+1 day), Day 12 (¬±1 day)/TOC, and Day 
28 (¬±2 days)  by [CONTACT_266508]:  
Sulopenem is an investigational thio penem antibiotic being developed for treatment of uUTI,  
complicated urinary tract infections (cUTI) , and complicated intra -abdominal infections 
(cIAI). Sulopenem etzadroxil is an oral pro- drug of sulopenem. Upon oral absorption, 
sulopenem etzadroxil  is expected to be rapi[INVESTIGATOR_259473], the active 
moiety .   
Sulopenem possesses potent activity against species of the Enterobacter ales including those 
that encode Extended Spectrum Œ≤ -lactamase ( ESBL ) or AmpC -type Œ≤ -lactamases that confer 
resistance to third generation cephalosporins. Sulopenem etzadroxil is expected to be the first 
oral penem for uUTI on the market in the [LOCATION_002] and Europe and will offer the option 
of treatment in the outpatient setting as well as intravenous ( IV) to oral switch therapy for 
early discharge of patients hospit alized with serious , complicated infections.  Probenecid, co -
administered with the oral prodrug, in a bilayer tablet formulation, will reduce renal clearance 
and increase systemic exposure of the active moiety, sulopenem  (CP-70,429) .   
 
This trial is a prospective Phase 3, randomized, multicenter, double -blind, double dummy, 
controlled study to compare oral sulopenem etzadroxil /probenecid (oral sulopenem) to oral 
amoxicillin/clavulanate  for the treatment of patients with uUTI .  Approximately 1966 adult 
women with uUTI will be randomized in a 1:1 fashion to receive either a bilayer tablet with  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 5 of 84 sulopenem etzadroxil /probenecid 500 mg /500 mg  twice daily for 5 days or oral 
amoxicillin/clavulanate 875 mg/ 125 mg twice daily for 5 days.  
The primary outcome measure for efficacy evaluation will be the overall success (combined 
clinical  and microbiologic success) on Day 12 (¬± 1 day) /TOC  in the micro -MITT, micro -
MITTS and micro -MITTR populations .  
The micro -MITT population will be comprised of all randomized patients who received at 
least one dose of study drug and had ‚â•105 CFU/mL of a baseline pathogen (Enterobacterales 
or Staphylococcus saprophyticus  only) isolated from a urine culture specimen taken at 
baseline, prior to initiation of study drug therapy.  
 The primary comparison of the study is in the micro- MITT population (the combined 
population of patients with a positive baseline culture and without regard to amoxicillin/clavulanate susceptibility). These outcomes are most relevant to the practicing 
clinician who must choose empi[INVESTIGATOR_266486]. 
From a regulatory perspective, these results will help put into context the outcomes in the 
culture and susceptibility - driven subpopulations.  
The primary comparisons for regulatory approval are in two mutually exclusive sub -
populations of the micro -MITT population defined by a baseline characteristic, the micro -
MITTS and micro -MITTR populations:  
 
‚Ä¢ The micro -MITTS population: the subset of patients whose baseline pathogens are 
determined to be susceptible (MIC ‚â§ 8/4 mg/L) to the comparator study drug, 
amoxicillin/clavulanate.  
‚Ä¢ The micro -MITTR population : the subset of patients whose baseline pathogen is 
determined to be non- susceptible  [intermediate (MIC 16/8 mg/L) or resistant (MIC ‚â• 
32/16 mg/L)]  to the comparator study drug, amoxicillin/clavulanate . 
Amoxicillin/clavulanate breakpoints as per Clinical Laboratory Standards Institute (CLSI) 
(M100 Performance Standards for Antimi crobial Susceptibility Testing, 32
nd edition ).  
Study Population:  
A total enrollment of approximately 1966 patients is  planned.   
Patients will be randomized using an Interactive Web Randomization System ( IWRS ) into the 
study, provided they have satisfied all patient selection criteria.     
Inclusion Criteri a: 
1. Female patients ‚â•1 8 years of age with ‚â• 24 hours  and ‚â§96 hours of urinary symptoms 
attributable to a UTI  
2. Two of the following signs and symptoms of uUTI: urinary frequency, urinary 
urgency, pain or burning on micturition, suprapubic pain 
3. A mid -stream urine specimen with :  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 6 of 84 a. a machine- read dipstick positive for nitrite AND any positive leukocyte 
esterase  
OR,  
b. evidence of pyuria alone as defined by [CONTACT_5640]:  
i. a machine- read dipstick  positive for large leukocyte esterase OR   
ii. at least 10 white blood cells per cubic millimeter on microscopic 
analysis of unspun urine OR   
iii. White blood cell count ‚â•10 cells/HPF in the sediment of a spun urine  
4. Has given written informed consent to participate in the study  
Exclusion Criteria:  
1. Presence of signs and symptoms suggestive of acute pyelonephritis defined as: fever 
(temperature > 38¬∞ Celsius), chills, costovertebral angle tenderness, flank pain, nausea, and/or vomiting  
2. Receipt of antibacterial drug therapy potentially effective as treatment of uUTI within the prior [ADDRESS_324387] on outcome 
evaluations in patients with uUTI, including analgesics (e.g., non- steroidal anti-
inflammatory drugs, aspi[INVESTIGATOR_248], paracetamol etc.), ph enazopyridine, and cranberry 
products. Note: Patients can be included if these medications were previously taken 
and have ceased at the time of Screening onward.  
4. Any anatomical abnormality of the urinary tract, including surgically modified urinary tract anatomy, and obstructive uropathy due t o nephrolithiasis, stricture, tumor, or 
fibrosis 
5. Ongoing urinary retention  
6. Neurogenic bladder  
7. Current resident of a long- term care facility  
8. Instrumentation of urinary tract in the previous [ADDRESS_324388]  
11. Current urine culture, if available while evaluating eligibility, that is positive for more than 2 microorganisms regardless of colony count (contaminated), or confirms a fungal  
UTI 
12. Receiving hemodialysis, hemofiltration, peritoneal dialysis, or had a renal transplant  
13. Immunocompromised as evidenced by [CONTACT_39132]:  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 7 of 84 ‚Ä¢ Known HIV positive, with either a recent (in the past 6 months) AIDS -defining 
condition or a CD4 + T lymphocyte count <200/mm3  
‚Ä¢ Known neutropenia (defined as absolute neutrophil count <1000 cells/mm3) 
‚Ä¢ Systemic or hematological malignancy requiring chemotherapeutic or 
radiation/immunologic interventions within 6 weeks prior to randomization or 
anticipated to begin prior to completion of study 
‚Ä¢ Immunosuppressive therapy, including maintenance corticosteroid therapy 
(>40 mg/day equivalent prednisolone for 5 days or more in the 30 days prior to 
randomization) 
14. Known liver function abnormalities as defined by [CONTACT_266509]:  
‚Ä¢ ALT or AST > 3x upper limit of normal, and/or  
‚Ä¢ Total bilirubin > 2x upper limit of normal  
15. Females of child -bearing potential who are unable to take adequate contraceptive 
precautions (refer to Sections  4.4 and 4.5), have a positive pregnancy test result  within 
24 hours of study entry, are otherwise known to be pregnant, or are currently 
breastfeeding  
16. Poorly controlled Diabetes mellitus, including the presence of ketoacidosis and hyperosmolar hyperglycemia  
17. History of seizures  
18. History of blood dyscrasias  
19. History of uric acid kidney stones  
20. Acute (current) gouty a rthritis  
21. Concomitant administration of valproic acid  
22. History of allergy or hypersensitivity to carbapenems, Œ≤ -lactams or probenecid, as 
formulated with their excipi[INVESTIGATOR_840]  
23. Unlikely to survive the 4- week study period or has a rapi[INVESTIGATOR_266487], including septic shock, associated with a high risk of mortality  
24. The use of any other investigational drug in the [ADDRESS_324389] of care , 
prior to obtaining informed consent , may be used to assess eligibility for enrollment into study  
and/or for baseline urine cult ure. IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -[ADDRESS_324390], Dose, and Mode of Administration:  
Patients will be randomized to receive either a n oral  bilayer tablet with sulopenem 
etzadroxil /probenecid 500 mg/500 mg  PO twice daily for 5 days  or oral 
amoxicillin /clavulanate 875 mg/[ADDRESS_324391] pathogens isolated from urine cultures that are resistant to 
amoxicillin/clavulanate or carbapenems may be allowed to continue on study drug therapy to 
complete the 5- day duration of treatment based on clinical response and investigator 
judgement and are not required to receive alternative antibiotic therapy.  
Adjunctive Systemic Antibiotics (Rescue Therapy)  
In general, adjunctive systemic antibiotics are not allowed  for patients  enrolled in the study.   
At any time during the study period, and at the discretion of the principal investigator (PI), 
additional antibiotics ‚Äîoral or IV, as appropriate ‚Äîcan be prescribed as rescue therapy, e.g., in 
the event of worsening signs and symptoms of uUTI, or if the patient develops fever and/or flank pain suggestive of upper urinary tract involvement. In the event that rescue therapy is 
prescribed, patient symptoms will be collected as an unscheduled event ; such patients will be 
considered as treatment failures and  will be asked to still complete all protocol -specified 
assessments through the F inal Visit. Use of adjunctive antibiotics without clinical symptoms is 
strongly discouraged.  
Other Systemic Antibiotics:  
For Clostridioides  difficile  infections, metronidazole (IV or oral), vancomycin (oral or rectal) , 
or fidaxomicin (oral) may be used in both treatment groups. Patients with a co- infection with a 
gram -positive uropathogen known or suspected to be resistant to study drugs are allowed to 
receive agents with narrow spectrum gram -positive coverage (such as oral linezolid) at the 
discretion of  the investigator . 
Formulation and Packaging: 
Sulopenem etzadroxil treatment group:   The study drug will be supplied as a study kit 
containing one bottle with 10 bilayer tablets containing sulopenem etzadroxil /probenecid 500 
mg/500 mg and one blister wallet containing 10 amoxicillin/clavulanate placebo  capsules . 
Comparator treatment group:  The study drug will be supplied as a study kit containing one 
blister wallet containing  10 over- encapsulated amoxicillin /clavulanate 875 mg/125 mg tablets , 
and one bottle with 10 placebo tablets to match sulopenem etzadroxil/probenecid tablets.   IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 9 of 84 Preparation and Dispensing : 
Each patient will receive a treatment kit containing one 5- day treatment course of either 
sulopenem etzadroxil /probenecid and placebo amoxicillin/clavulanate  or placebo sulopenem 
etzadroxil /probenecid and amoxicillin/clavulanate . 
Administration : 
Patients  randomized to the sulopenem treatment group will take one sulopenem 
etzadroxil /probenecid tablet and one  placebo capsule twice daily for 5 days and those 
randomized to the amoxicillin/clavulanate treatment group  will take one over- encapsulated 
amoxicillin/clavulanate tablet and  one placebo tablet  twice daily  for 5 days (10 doses total  
over a 5 -day period; if Dose 1 is taken in the evening of Day 1, Dose 10 will  be taken in t he 
morning of Day 6) . The first dose of each medication will be administered under the 
supervision of study site personnel  to help ensure compliance with dosing directions . 
Dosing with food:  
Food significantly increases bioavailability of sulopenem and consequently results in 
decreased rates of diarrhea. Therefore, dosing of oral sulopenem with food whenever possible 
is recommended.  Since adequate target attainment appears to be achieved in t he fasted state, 
an inability to administer the dose with food should not preclude dosing.  
Amoxicillin and clavulanate are well absorbed from the gastrointestinal tract after oral 
administration. Dosing in the fasted or fed state has minimal effect on the  pharmacokinetics of 
amoxicillin. While amoxicillin/clavulanate can be given without regard to meals, absorption of clavulanate when taken with food is greater relative to the fasted state. Therefore, dosing of 
oral amoxicillin/clavulanate with food whenev er possible is also recommended.  
Efficacy Assessments: 
 
The assessment of clinical response includes a review of the following symptoms  at the 
Baseline, Day 5 ( +1 day) /End of Treatment ( EOT ) visits , and the Day 12 (¬± 1 day) /TOC , and 
Day 28 (¬± 2 days)  visits or at P remature Discontinuation : urinary frequency, urinary urgency, 
pain or burning on micturition, and suprapubic pain.  
Microbiologic response assessments will be made based on quantitative cultures performed on collected urine specimens  at the Baseline, Day 5 ( +1 day) , Day 12 (¬± 1 day) /TOC , and Day 28 
(¬± 2 days)  visits or at Premature Discontinuation. 
Results of susceptibility testing to differentiate between pathogens isolated at baseline and follow- up visits will be used in a sensitivity analysis to be specified in the statistical analysis 
plan ( SAP); whole genome sequencing (WGS) may be performed if needed and results will be 
used in a sensitivity analysis to be specified in the  SAP.  
 IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 10 of 84 Safety Assessments:  
Safety will be assessed by [CONTACT_104542], collection of adverse events and clinical 
laboratory tests.  
A targeted p hysical examination will be performed at the Baseline visit, and a targeted exam 
will be conducted if needed ( as determined by [CONTACT_093]) at Day 5 ( +1 day) , Day 12 (¬± 1 
day)/TOC , Day 28 (¬± 2  days) visits or at Premature Discontinuation; vital signs will be 
collected at the Baseline visit, and at Day 5 (+ 1 day), and Day 12 (¬± 1 day) /TOC  or Premature 
Discontinuation. Adverse events will be collected at every visit, beginning from the signing of 
Informed Consent. Clinical laboratory tests will be obtained at the Baseline visit, the Day 12 
(¬± 1 day) /TOC  visit, in follow- up of any clinically significant laboratory finding s, as well as at 
Premature Discontinuation.  
Statistical  Methods:  
Sample Size Considerations:   
Study IT001-310 is designed to determine whether oral sulopenem is non- inferior  to oral 
amoxicillin/clavulanate for the outcome measure of overall success (combined clinical and 
microbiologic success) at Day 12 (¬± 1 day) /TOC  in both the micro -MITT and micro -MITTS 
populations and whether oral sulopenem is superior to oral amoxicillin/clavulanate for overall 
success at Day 12 (¬± 1 day) /TOC  in the micro -MITTR population.  The primary outcome 
measure of overall success (combined clinical and microbiologic success) is defined as 
resolution of the symptoms of uUTI present at trial entry with  no new symptoms, and the 
demonstration that the bacterial pathogen found at trial entry is reduced to <103 CFU/mL on 
urine culture.  
The proposed sample size in the micro- MITTS population is 505 patients per arm (total 
sample size of 1010 patients)  based o n the method of Farrington and Manning. This assumes a 
non-inferiority margin of 10.0%, a power of 90%, a one -sided alpha level of 0.025 , 60% 
overall  success rate with amoxicillin/clavulanate and 6 0% overall success rate with sulopenem 
etzadroxil /probenecid. Assuming that 21 % of the patients will have non -susceptible pathogens 
to amoxicillin/clavulanate and assuming 85% power to show superiority in the micro- MITTR 
population ( micro -MITT= 1278 patients ), 67% of the randomized patients will meet criteria for 
inclusion into the micro- MITT population ( MITT= 1907 patients)  and allowing for a dropout 
rate of 3%, the sample size for the ITT population is 1966. With [ADDRESS_324392] 85% power to show superiority at the 
one-sided 2.5% alpha level given a 51% and 33% overall success rate in the oral sulopenem 
and amoxicillin/clavulanate groups, respectively.  With [ADDRESS_324393] 95% power to show non- inferiority (non- inferiority margin of 
10.0%) at the one -sided alpha level of 0.025 with the treatment success rates of the oral 
sulopenem and amoxicillin/clavulanate  groups assumed to be 58% in this population . 
To ensure that the point estimate of overall success (combined clinical and microbiologic 
success) used in the estimation of sample size, and the estimated eligibility rate, 
susceptibility rate, and rate of post -treatmen t asymptomatic bacteriuria is valid for this study, 
an interim analysis for sample size re -estimation will be performed when clinical and 
microbiologic response data at Day 12 (¬± 1 day)/TOC are available for approximately 50% 
of the patients ( approximately  983 patients ) (see Section 9.7). The FDA Guidance ‚ÄúNon -IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 11 of 84 inferiority Clinical Trials‚Äù [ FDA Guidance 2016 ] notes that such a sample size re -estimatio n 
if based on the blinded overall response rates is not only acceptable but is advisable.  The 
interim analysis will involve a sample size re -estimation to either confirm the initial sample 
size estimate is adequate or increase the sample size (number of r andomized patients) to 
ensure the study has adequate power. The sample size of the study will be computed to 
ensure that there is sufficient power for determining whether oral sulopenem is NI to oral amoxicillin/clavulanate for the primary outcome measure in the micro -MITTS population. 
This will ensure that the study is sufficiently powered to test the primary endpoint in the micro -MITT and micro -MITTR populations as well. The sample size will not be decreased  
after the interim analysis .  In addition, the s ample size may be increased based on a lower -
than-expected evaluability rate (i.e., percentage of the ITT population in the micro- MITT 
population), higher - than-expected rate of asymptomatic bacteriuria or lower than expected 
percentage of patients with a susceptible pathogen. The sample size re- estimation will be 
based on the blinded overall (not by [CONTACT_1570]) pooled data.  If the aggregated overall 
success rate in the micro -MITTS population is higher than 70%, or if the aggregated rate of 
asymptomatic bacteriuria  is significantly lower than anticipated, then a futility analysis may 
be conducted by [CONTACT_266510]. Further details of how the 
DMC will decide to do the futility analysis, how the sponsor will be involved and how the 
analysis will be conducted will be provided in the SAP and the DMC charter . 
 IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 12 of 84 General Statistical Considerations:    
Descriptive statistics, including the numbers and percentages for categorical variables, and the 
numbers, means, standard deviations, medians, minimums, and maximums for continuous 
variables will be provided. All comparisons will be for oral sulopenem versus oral 
amoxicillin/clavulanate . Exploratory analyses may also be performed.  Listings of individual 
patient‚Äôs data will be produced.  
A comprehensive Statistical Analysis Plan (SAP) will be finalized and submitted to the FDA  
prior to the interim analysis.  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 13 of 84 Efficacy Analyses:    
Analysis of Primary Outcome Measure:  
The study is designed to determine whether oral sulopenem is NI to oral 
amoxicillin/clavulanate for the outcome measure of overall success (combined clinical and 
microbiologic success ) at Day 12 (¬± 1 day) /TOC  in the micro -MITT and micro -MITTS 
populations and whether oral sulopenem is superior to oral amoxicillin/clavulanate  for overall 
success  at Day 12 (¬± 1 day) /TOC  in the micro -MITTR popula tion.  
A patient will be defined as an overall success  if the following criteria are met:  
‚Ä¢ The patient is alive  
‚Ä¢ The patient has received no rescue therapy for uUTI  
- If an antibiotic active against the urinary tract pathogen is given for other reasons, then 
the patient will be considered indeterminate  
‚Ä¢ The patient has resolution of the symptoms of uUTI present at trial entry and no new uUTI 
symptoms (based on the Patient Symptom Assessment Questionnaire)  
‚Ä¢ Urine culture taken on Day 12 (¬± 1 day) /TOC  demonstrates <103 CFU/mL of the baseline 
uropathogen based on results of quantitative cultures performed on collected urine 
specimens.   
All other patients will be considered as failures  unless data are unavailable to determine if 
the patient is a success  or a failure. In this case, the patient will be considered as having an 
indeterminate response. Patients with an indeterminate response are included in the denominator for determination of the  overall  success  rate. 
 
The number and percentage of patients with s uccess , failure  and indeterminate  outcomes will 
be determined in each treatment group in the micro -MITT, micro -MITTS and micro -MITTR 
populations . For each analysis population, the obs erved difference in the percentage of 
patients with success  at Day 12 (¬± 1 day) /TOC  (oral sulopenem group minus the 
amoxicillin/clavulanate  group) will be determined and a two -sided 95% confidence interval 
(CI) for the observed difference will be computed using the method proposed without 
stratification by [CONTACT_240865].  
The framework for the statistical hypothesis testing of the primary efficacy outcome, overall 
success  (combined clinical and microbiological success ) at Day 12 (¬± 1 day) /TOC , is d efined 
below.  
The primary comparison of the study is in the micro- MITT population ( the combined 
population of patients with a positive baseline culture and without regard to amoxicillin/clavulanate susceptibility). These outcomes are most relevant to the practicing 
clinician who must choose empi[INVESTIGATOR_266486]. 
From a regulatory perspective, these results will help put into context the outcomes in the 
culture and susceptibility - driven subpopulations.  
The primary comparisons for regulatory approval are in two mutually exclusive sub -
populations  of the micro -MITT population defined by a baseline characteristic :  1) the micro -IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 14 of 84 MITTS population (the subset of the micro -MITT population in which the baseline pathogen 
is determined to be susceptible to the comparator study drug, amoxicillin/clavulanate ); and 2) 
the micro -MITTR population (the subset of the micro- MITT population in which the baseline 
pathogen is determined to be non-susceptible [intermediate (MIC 16/8 mg/L) or resistant 
(MIC ‚â• 32/16 mg/L)] to the comparator study drug, amoxicillin/clavulanate).  
To control for inflation of the  overall type I error rate, the hierarchical testing procedure of 
Westfall and Krishen (Westfall 2001) will be used to test the hypotheses of the primary 
efficacy outcome in these populations in the sequential order described below. Testing will 
proceed to the next comparison, only in the case where the null hypothesis in the previous 
comparison was rejected. When testing in a sequential manner with pre- planned testing, no 
adjustment to the alpha level is required  
(1) NI in the micro -MITT population.  For this population, a NI test of the overall success rate 
will be conducted.  The null and alternative hypotheses are the following:  
‚àÜ ‚àí ‚â§ ‚àí2 1 0 : p p H  and ‚àÜ ‚àí > ‚àí2 1 : p p HA , 
where p 1 is the primary efficacy outcome rate in the oral sulopenem group, p 2 is the primary 
efficacy outcome rate in the amoxicillin/clavulanate group, and Œî is the non- inferiority margin 
of 10.0 %. 
The NI hypothesis test is a 1- sided hypothesis test performed at the 2.5% level of significance.  
This is based on the lower limit of the 2- sided 95% CI for the observed difference in the 
overall success rate (oral sulopenem group minus amoxicillin/clavulanate group).  The 
primary analysis is based on the CI computed using the method proposed without stratification 
by [CONTACT_240865], which corresponds to the p- value approach of the Farrington-
Manning test.  If the lower limit of the 95% CI for difference in success rates in the micro -
MITT population is greater th an -10.0%, the null hypothesis will be rejected and the NI of oral 
sulopenem to amoxicillin/clavulanate will be concluded.  
 (2) NI in the micro -MITTS population OR superiority in the micro- MITTR population as 
described below : 
Micro-MITTS population: the su bset of the micro -MITT population in which the baseline 
pathogen is determined to be susceptible to the comparator study drug, amoxicillin/clavulanate. For this population, a NI test of the o verall success rate will be 
conducted. The null and alternative hypotheses are as follows:  
‚àÜ ‚àí ‚â§ ‚àí2 1 0 : p p H  and ‚àÜ ‚àí > ‚àí2 1 : p p HA  
A 2-sided 95% CI for the o bserved treatment difference in success rates will be determined. If 
the lower bound of the 95% CI is greater than - 10.0%, the null hypothesis will be rejected and 
the NI of oral sulopenem to amoxicillin/clavulanate in the micro -MITTS population will be 
concluded. 
Micro-MITTR population: the subset of the micro- MITT population in which the baseline 
pathogen is determined to be non-susceptible to the comparator study drug, 
amoxicillin/clavulanate . For this population, a superiority test will be conducted.  The null and 
alternative hypotheses are as follows:  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 15 of 84 2 1 0 : p p H= and 2 1 : p p HA‚â† 
A 2-sided 95% CI for the o bserved treatment difference in success rates will be determined 
using the method without stratification of Miettinen and Nurminen.  If the lower bound of the 
95% CI is greater than 0%, the null hypothesis will be rejected and superiority of oral 
sulopenem to amoxicillin/clavulanate will be concluded in the micro -MITTR population.  
Each of the 2 null hypotheses in this step will be tested at the 2.5% level and if either hypothesis is rejected, then testing will proceed to the next step.  
(3) Superiority test of overall success, ùêªùêª
0:ùëùùëù1=ùëùùëù2 and ùêªùêªùê¥ùê¥:ùëùùëù1‚â† ùëùùëù2, in the micro -MITT 
population. If the lower bound of the 95% CI (calculated for the hypothesis test in (1) is 
greater than 0%, the null hypothesis will be rejected and the superiority of oral sulopenem to amoxicillin/clavulanate in the micro -MITT population will be concluded.  
Analysis of Secondary Efficacy Outcome Measure:  
The number and percentage of patients in each treatment group with a clinical response of 
success, failure and indeterminate at Day 12 (¬±1 day) /TOC will be presented for the MITT, 
micro -MITT, micro -MITTS, and micro -MITTR populations. The number and percent age of 
patients in each treatment group with a clinical response of success and failure at Day 12 (¬±1 
day)/ TOC will be presented for the CE and ME populations.  Two- sided 95% unstratified  CIs 
will be constructed for the obs erved difference in the clinical success  rates between the 
treatment groups for descriptive purposes ; no conclusion of NI will be made.  
The number and percentage of patients in each treatment group with asymptomatic bacteriuria 
at Day 12 (¬±1 day) /TOC will be presented for the micro -MITT, micro -MITTS, micro -MITTR 
and ME populations . The difference in rate of asymptomatic bacteriuria (oral sulopenem group 
minus the amoxicillin/clavulanate  group) will be determined and 2-sided 95% unstratified CIs 
will be constructed for the obs erved differen ce between the treatment groups for descriptive 
purposes; no conclusion of NI will be made.  
 The number and percentage of patients in each treatment group with a microbiologic response 
of success, failure and indeterminate at Day 12 (¬±1 day) /TOC will be pr esented for the micro -
MITT, micro -MITTS, and micro -MITTR populations. The number and percentage of patients 
in each treatment group with a microbiologic response of success and failure at Day 12 (¬±1 
day)/ TOC will be presented for the ME population.  Two- sided 95% unstratified CIs will be 
constructed for the observed difference in the microbiologic success  rates between the 
treatment groups for descriptive purposes ; no conclusion of NI will be made.  
 
Safety analyses will be conducted in the Safety population (all patients who received at least 
one dose of study drug) and will be summarized by [CONTACT_1570].  Safety will be assessed through summaries of AEs, laboratory evaluations, and vital signs.  
 IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -[ADDRESS_324394] OF ABBREVIATIONS AND DEFINITIONS OF TERMS  ........................................ 20  
1 INTRODUCTION ....................................................................................................... 23  
1.1 Indication........................................................................................................... 23  
1.2 Background and Rationale  ................................................................................. 23  
1.2.1  Safety data  ............................................................................................... 28  
[IP_ADDRESS]  Sulopenem etzadroxil ( PF-03709270; oral prodrug)  ........................ 28  
[IP_ADDRESS]  Sulopenem (CP -70,429; Intravenous)  ............................................. 29  
1.2.2  Rationale for Study  .................................................................................. 30  
1.2.3  Dose Rationale  ......................................................................................... 32  
2 STUDY OBJECTIVES  ............................................................................................... 33  
2.1 Objectives  .......................................................................................................... 33  
3 STUDY DESIGN  ........................................................................................................ 34  
3.1 Investigational Study Medications  ..................................................................... 35  
3.2 Adjunctive Systemic Antibiotics  ........................................................................ 35  
3.3 Additional Non- Study Therapy Antibiotics  ........................................................ 35  
4 STUDY POPULATION SELECTION ........................................................................ 35  
4.1 Inclusion Criteria  ............................................................................................... 35  
4.2 Exclusion Criteria  .............................................................................................. 36  
4.3 Randomization Criteria  ...................................................................................... 37  
4.4 Lifestyle Guidelines  ........................................................................................... 37  
4.5 Women of Child- Bearing Potential  .................................................................... 38  
5 STUDY TREATMENTS ............................................................................................. 38  
5.1 Allocation to Treatment  ..................................................................................... 38  
5.2 Drug Supplies  .................................................................................................... 38  
5.2.1  Formulation and Packaging ...................................................................... 38  
5.2.2  Preparation and Dispensing ...................................................................... 39  
5.2.3  Administration  ......................................................................................... 39  
5.2.4  Compliance .............................................................................................. 39  
5.3 Drug Storage and Drug Accountability  .............................................................. 40  
5.4 Concomitant Medication(s), Adjunctive Therapy, and Non- drug Therapy  .......... 40  
5.4.1  Concomitant Medications  ......................................................................... 40  
5.4.2  Adjunctive Systemic Antibiotics (Rescue  Therapy) .................................. 40  
5.4.3  Additional Non- Study Therapy Antibiotics  .............................................. 40  
6 STUDY PROCEDURES  ............................................................................................. 41  
6.1 Screening (Day  -1) - Within [ADDRESS_324395] Dose  .................................. 41  
6.2 Treatment Period  ............................................................................................... 42  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 17 of 84 6.2.1  Day 1 ....................................................................................................... 42  
6.2.2  Day 5 (+ 1 day) (End of Treatment/EOT)  ................................................. 42  
6.3 Follow- up Period  ............................................................................................... 42  
6.3.1  Day 12 (¬± 1 day) (Test of Cure/TOC)  ....................................................... 42  
6.3.2  Day 28 (¬± 2 days) (Final Visit/FV)  ........................................................... 43  
6.4 Premature Discontinuation  ................................................................................. 43  
6.5 Patient Withdrawal from Treatment or Study  ..................................................... 44  
7 ASSESSMENTS  ......................................................................................................... 44  
7.1 Safety  ................................................................................................................ 44  
7.1.1  Physical Examination  ............................................................................... 44  
7.1.2  Vital Signs (Temperature, Blood Pressure, Pulse  Rate, Respi[INVESTIGATOR_13581])  . 44 
7.1.3  Clinical Laboratory Assays  ...................................................................... 44  
7.1.4  Clinically Significant Laboratory Tests  .................................................... 45  
7.2 Efficacy  ............................................................................................................. 45  
7.2.1  Overall Response  ..................................................................................... 45  
7.2.2  Microbiologic ........................................................................................... 46  
7.2.3  Patient -Determined Clinical Response  ...................................................... 46  
7.2.4  Investigator Assessment of Clinical Response  .......................................... 47  
7.2.5  Patient Symptom Assessment Questionnai re (PSAQ)  ............................... [ADDRESS_324396] Findings ..................................................................................... 49  
8.5 Serious Adverse Events (SAE)  ........................................................................... 49  
8.6 Hospi[INVESTIGATOR_059]  ................................................................................................... 50  
8.7 Severity Assessment  .......................................................................................... 51  
8.8 Causality Assessment ......................................................................................... 51  
8.9 Exposure during Pregnancy  ............................................................................... 52  
8.10  Discontinuation from Study Drug Due to AEs (See also Patient Withdrawal, 
Section  6.5)........................................................................................................ 53  
8.11  Eliciting AE Information  ................................................................................... 53  
8.12  Reporting Requirements  .................................................................................... 53  
8.12.1  SAE Reporting Requirements  ................................................................... 53  
8.12.2  Non-SAE Reporting Requirements  ........................................................... 54  
8.12.3  Sponsor Reporting Requirements to Regulatory Authorities  ..................... 54  
9 DATA ANALYSIS/STATISTICAL METHODS  ........................................................ 54  
9.1 Sample Size Determination  ................................................................................ 54  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -[ADDRESS_324397] KEEPI[INVESTIGATOR_1645]......................................................... 62  
11.1  Case Report Forms / Electronic Data Record  ..................................................... [ADDRESS_324398] (IRB)/Independent Ethics Committee (IEC)  ............ [ADDRESS_324399]  ..................................................................................................... 66  
APPENDIX 1     RATIONALE FOR AMOXICILLIN/CLAVULANATE AS 
COMPARATOR IN UNCOMPLICATED UTI TRIAL  .............................................. 69  
APPENDIX 2   SCHEDULE OF STUDY ASSESSMENTS  ............................................ 78  
APPENDIX 3   MICROBIOLOGY  .................................................................................. 79  
APPENDIX 4  CRITERIA FOR SAFETY LABORATORY VALUES OF POTENTIAL 
CLINICAL CONCERN  .............................................................................................. 81  
APPENDIX 5   SUMMARY OF CHANGES  ................................................................... 82  
Appendix 5.1   Amendment 1  ................................................................................ 82  
APPENDIX 6 INVESTIGATOR‚ÄôS SIGNATURE  .............................................................. 84  
 
  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -[ADDRESS_324400] of In -Text Table s 
Table 1   Sulopenem In- Vitro Susceptibility (2013-2015) .................................................... 25  
Table 2  Comparison of Optimal and Alternative Treatment Regimens, IDSA Guidelines  .. 71  
Table 3   Resistance Rate for Baseline Pathogen(s), IT001 -301 ........................................... 74  
Table 4   Overall Response at TOC by [CONTACT_266511], IT001- 302, micro- MITT 
Population .................................................................................................... 76  
 
 
 IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -[ADDRESS_324401] Infection  
DMC  Data Monitoring Committee  
EARS -NET  European Antimicrobial Resistance Surveillance Network  
ECG  Electrocardiogram  
E. coli Escheri chia coli  
eCRF  Electronic case report form  
EDC  Electronic data capture  
EIU Exposure in Utero  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 21 of 84 EOT  End of Treatment Visit  
ESBL  Extended Spectrum Beta-lactamase  
FDA  Food and Drug Administration  
FSH Follicle -stimulating Hormone  
FV  Final Visit   
GCP  Good Clinical Practice  
GGT  Gamma -glutamyl Transpeptidase  
GMP  Good Manufacturing Practic e 
hERG  Human Ether -a-go-go-Related Gene  
HIV Human Immunodeficiency Virus  
HPF High power field  
hs-CRP  High -sensitivity C -reactive Protein  
ICH International Conference on Harmonisation  
ICF Informed Consent Form  
IDSA  Infectious Disease Society of America  
IRB/IEC  Institutional Review Board /Independent Ethics Committee  
ITT Intent -to-Treat  
IUD Intrauterine Device  
IV Intravenous  
IWRS Interactive Web R esponse  System  
LDH  Lactate Dehydrogenase  
LTFU  Lost to Follow -Up 
ME Microbiologically Evaluable  
MedDRA  Medical Dictionary of Regulatory Activities  
MIC  Minimal Inhibitory Concentration  
MITT  Modified ITT  
Micro -MITT  Micro biologic -MITT  
Micro -MITTR  Micro biologic -MITT  Resistant  
Micro -MITTS  Micro biologic -MITT  Susceptible  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 22 of 84 NI Non-inferior /Non -inferiority  
NOAEL  No Observed Adverse Effect Level  
PBP Penicillin -Binding Proteins  
PCS Potentially clinically significant  
PK Pharmacokinetic  
PK/PD  Pharmacokinetic / Pharmacodynamic  
PO Per-oral 
PSAQ  Patient symptom assessment questionnaire  
PT Preferred Term  
PV Pharmacovigilance  
RBC  Red Blood Cell  
SAE  Serious Adverse Event  
SAP Statistical Analysis Plan  
SOC  System organ class  
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reaction  
TA Target Achievement  
TEAE  Treatment Emergent Adverse Event  
TOC  Test of Cure  
Tmax Time to maximum concentration  
USPI  [INVESTIGATOR_266488]  
2-EBA  2-Ethylbutryic Acid  
 
 IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 23 of 84 1 INTRODUCTION  
1.1 Indication 
Sulopenem and/or sulopenem etzadroxil/probenecid (oral sulopenem) are being studied for the 
treatment of the following indications:  
- Uncomplicated urinary tract infections  
- Complicated urinary tract infections 
- Complicated intra -abdominal infections  
1.[ADDRESS_324402] 50  years has resulted in the 
development of microbial resistance to these agents among clinically important bacteria.   This 
resistance commonly takes the form of Œ≤ -lactamase producti on, expression of porins in the 
bacterial outer membrane or alterations in penicillin -binding proteins (PBPs).   Such mechanisms 
have reduced the clinical utility of frequently prescribed Œ≤ -lactams such as amoxicillin, 
amoxicillin plus clavulanate (a Œ≤ -lactamase inhibitor), and cephalosporins.  The issue of 
resistance continues to drive the search for new compounds with increased stability and efficacy 
against resistant pathogens.  
The prevalence of infections caused by [CONTACT_89927]- spectrum Œ≤ -lactamase (ESBL) producing 
Enterobacterales  has been increasing worldwide and includes both hospi[INVESTIGATOR_307] -acquired and 
community onset infections. An analysis of data reported from 2011 to 2014 to the N ational 
Healthcare Safety Network performed by [CONTACT_104545] 2016 
revealed that the proportion of E. coli resistant to extended- spectrum cephalosporins causing 
hospi[INVESTIGATOR_307]- acquired infection was 13.4% nationally, with rates as high as 24% reported in some 
Northeastern, Southern , and Western states.  The same analysis also demonstrated that over a 
third of E.  coli isolates in 2014 were resistant to quinolones. Data reported by [CONTACT_259485] (EARS -NET) in Europe demonstrate that the 
prevalence of quinolone resistant E.  coli and E. coli resistant to third generation  cephalosporins 
is > 25% and E.  coli resistant to third  generation cephalosporins, aminoglycosides and 
quinolones has increased to >10% in some southern and eastern European countries.  
Oral antibiotic treatment options are extremely limited for patients with these multi-drug 
resistant infections, resulting in  lengthy hospi[INVESTIGATOR_259475], even for those with uncomplicated infections. The currently available oral antibiotics with activity against ESBL producing organisms include nitrofurantoin, fosfomycin, quinolones, 
and trimethoprim -sulfamethoxazole. Nitrofurantoin and fosfomycin are only approved for the 
treatment of uncomplicated urinary tract infections in the [LOCATION_002], have rising rates of resistance and are associated with inferior efficacy  [Munoz- Davila 2014; Schito 2009] . 
Resistance to trimethoprim- sulfamethoxazole is uniformly above 20% in the US.  Increasing 
prevalence of resistance to quinolones and their propensity to cause collateral damage resulted in 
relegation of quinolones to second- line ther apy by [CONTACT_266512]001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 24 of 84 (IDSA) for uUTI  [Gupta 2011] . In a recent multicenter analysis of trends in resistance in >2.2 
million urinary Enterobacterales isolates from ambulatory patients in the [LOCATION_002] (2011 -
2020), resistance rates were 57.5%, 23.1%, 20.6%, and 20.2% for Œ≤ -lactams, trimethoprim-
sulfamethoxazole, fluoroquinolones, and nitrofurantoin, respectively, and 6.9% had an ESBL -
producing phenotype [ Dunne 2022].  Efficacy outcomes for patients treated with antibiotics  for 
uUTI caused by [CONTACT_105]- susceptible pathogens are not known, though a recent  analysis of 4,792 
patients with 5,395 evaluable outpatient UTI epi[INVESTIGATOR_1841], 22% of patients received an antibiotic to 
which the pathogen was resistant in vitro , and those patients were almost twice as likely to 
require a second prescription (34% versus 19%) or be hospi[INVESTIGATOR_057] (15% versus 8%) within 28 days of the initial prescription fill compared to patients who received an ant ibiotic to which the 
pathogen was susceptible [ Dunne 2022] .  
 
The currently proposed study will compare the safety, tolerability, and efficacy of oral 
sulopenem versus oral amoxicillin/clavulanate  for the treatment of uUTI  in women.  Sulopenem 
(CP-70,429) i s a broad -spectrum thiopenem Œ≤ -lactam antibiotic which is being developed for the 
treatment of infections caused by [CONTACT_7163] -drug resistant bacteria. Sulopenem possesses potent 
activity against species of the Enterobacterales  that encode ESBLs or AmpC -type Œ≤ -lactamases 
that confer resistance to third generation cephalosporins. The targeted g ram-negative spectrum of 
sulopenem is balanced by [CONTACT_266513], which is 
similar to that of imipenem.  
 
An in vitro susceptibility study of sulopenem was conducted in April 2016 utilizing 
contemporary clinical bacterial isolates from patients in the [LOCATION_002] and Europe. Minimal inhibitory concentrations (MICs) of sulopenem and [ADDRESS_324403] 
1,122 recent (2013- 2015) clinical isolates following Clinical and Laboratory Standards Institute 
(CLSI) guidelines.   The study collection included 872 aerobes (811 g ram-negative, 61 gram -
positive) and 250 anaerobes.  Isolates were chosen randomly from the IHM A (International 
Health Management Associates, Inc., Schaumburg, IL) repository, which is a global collection of 
single patient clinical isolates.    For this study, the selection of isolates focused on infection 
source (IAI and UTI) and region (US and Euro pe) for the inclusive years . Aerobes were tested 
by [CONTACT_104548]. Results from this study 
presented below demonstrate that sulopenem retains potent in vitro  activity against common 
pathogens implicated in urinary tract infections and intra -abdominal infections, including those 
that are caused by [CONTACT_104549] (data on file).  Carbapenem resistant 
Enterobacterales  (CRE) were excluded from the analysis shown below, but the MIC
90 of 
Enterobacterales  remains at 0.25 ¬µg/mL even if CRE are included, given that their overall 
prevalence is low (data on file) . 
  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 25 of 84  
Table 1   Sulopenem In- Vitro Susceptibility (2013 -2015) 
Organism Class  N MIC 50 
(¬µg/mL)  MIC 90 
(¬µg/mL)  
Enterobacterales  [ADDRESS_324404] 
for resistant P. aeruginosa as can occur with imipenem and meropenem.  
Sulopenem (CP-70,429) is available as an intravenous formulation. Intravenous sulopenem was 
previously evaluated in Phase 1 and Phase 2 clinical studies in Japan in approximately 1478 
subjects, at doses up to 1g BID administered intravenously over 3 -14 days in the early 1990s. 
Safety data collected from these trials regarding both adverse events as well as laboratory examinations provides support for the safety and tolerability of sulopenem in patients and its further development.   
Sulopenem etzadroxil, the oral pro- drug of sulopenem,  has minimal in vitro  antibacterial activity . 
Upon oral absorption, sulopenem etzadroxil  yields the active moiety sulopenem ( CP-70,429) in 
addition to the non- active moieties formate and 2- ethylbutyric acid (2- EBA).   
Sulopenem etzadroxil  has been studied in single and multiple dose Phase 1 studies, with and 
without co- administration of probenecid. One small Phase 2 study in patients with community 
acquired pneumonia was conducted, in which 35 adult patients were randomized to one of three 
treatment groups to receive either: a single loading dose of intravenous (IV) sulopenem with 
switch to oral sulopenem etzadroxil , 4 dose minimum of IV sulopenem with switch to oral 
sulopenem etzadroxil, or ceftriaxone (IV) for a minimum of 2 doses, with step down to amoxicillin/clavulanate. The cure rates in the clinically evaluable patients  in this study at TOC 
were 90%, 88% and 63% in the single IV dose sulopenem, multiple IV dose sulopenem and ceftri axone (IV) groups, respectively. While these efficacy results were not statistically 
significant due to the small numbers enrolled, they provide encouraging support for further 
clinical testing in this indication.   IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 26 of 84 Sulopenem (IV) has been studied in Phase  3 studies in patients with cUTI, and cIAI, and oral 
sulopenem has been studied in a Phase 3 study in patients with uUTI, as well as step -down 
therapy in patients in the cUTI and cIAI studies. These studies were conducted in the United 
States  and Eastern E urope. 
Study IT001-301: 
Study IT001-301 was a  prospective, Phase  3, randomized,  multi- center,  double-blind, double -
dummy study of the efficacy, tolerability, and safety of oral sulopenem versus  oral ciprofloxacin 
for treatment of uUTI in adult  women. A tot al of 1,671 adult women with uUTI were  
randomized in a 1:1 fashion to receive either a bilayer tablet with sulopenem 
etzadroxil/probenecid 500     mg/500 mg twice  daily  for 5 days or  oral ciprofloxacin  250 mg twice  
daily  for 3 days .  
The primary efficacy endpoint for the population of patients with organisms non- susceptible to 
quinolones ( micro -MITTR population ) was overall response at the Day 12 (¬±1 day) /TOC  Visit. 
Overall success was seen in 62.6% of patients in the sulopenem group and 36% of patients in the 
ciprofloxacin group (treatment difference 26.6%, 95% CI [15.1, 37.4]). The study demonstrated 
superiority of sulopenem to ciprofloxacin in the treatment of uUTI in the micro- MITTR 
population.  
In a second population of patients with organisms susceptible to quinolones (micro- MITTS 
population), oral sulopenem was not noninferior to ciprofloxacin for the primary endpoint of 
overall response .  The difference in overall success between the treatment groups in this 
population of patients was driven primarily by [CONTACT_266514] -
treatment  which was lower for patients receiving ciprofloxacin relative to those receiving 
sulopenem etzadroxil/probenecid.  
Overall response in the combined population of patients with a positive baseline culture and 
without regard to quinolone susceptibility, did not demonstrate a difference in treatment outcome.  
Overall, the safety profile for oral sulopenem  compared with ciprofloxacin was consistent across 
patient populations. The most common a dverse event seen in patients receiving oral sulopenem 
was diarrhea, which was mild  and self-limited.  The rates of discontinuations from study drug 
and SAEs were low on both regimens and similar between the two groups.  
Study IT001-302: 
Study IT001- 302 was a prospective, Phase 3, randomized, multi -center, double -blind, double -
dummy study of the efficacy, tolerability and safety of sulopenem IV followed by [CONTACT_266515]/clavulanate for 
treatment of cUTI in adults. A  total of 1395 patients  were enrolled  in the study, randomly 
assigned  in a 1:1 ratio to sulopenem 1000 mg IV once daily for 5 days followed by [CONTACT_266516] 500 mg/500 mg twice daily to complete 7 -10 total days of treatment (N  = 697) 
or ertapenem  1000 mg IV once daily for 5 days followed by [CONTACT_266517] 500 mg 
twice daily to complete 7 -10 total days of treatment  (N = 698). Patients with a baseline 
pathogen non- susceptible to ciprofloxacin, but susceptible to amoxicillin/clavulanate, and who 
met criteria for oral step -down took amoxicillin/clavulanate 875 mg/125 mg  twice daily instead 
of ciprofloxacin to complete the 7- 10 total days of treatment.  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 27 of 84 In Study 302, t he primary  efficacy  endpoint was overall  response at the Day 21 (TOC)  Visit in 
the micro -MITT  population. Overall  success  was seen in 67.8% of patients  in the sulopenem 
group and 73.9% of patients  in the ertapenem  group in the  micro -MITT  population (treatment  
difference -6.1%, 95% CI [-12.0, - 0.1]);  because the lower  bound of the CI was less than the NI 
margin of  -10, the study did not demonstrate noninferiority of  sulopenem to ertapenem  in the 
treatment of  cUTI.  
Sulopenem was well -tolerated, with both the rate of discontinuations and the incidence of 
TEAEs similar to those of ertapenem. The rate of SAEs for patients on sulopenem was similar to 
that for patients on ertapenem.  
Study IT001-303: 
Study IT001- 303 was a prospective Phase 3, double -blind, multicenter, randomized study of the 
efficacy and safety of sulopenem IV followed by [CONTACT_266518]/clavulanate for treatment of cIAI in adults.  A  
total of 674 patients  were enrolled  in the study, randomly assigned  in a 1:1 ratio to sulopenem 
1000 mg IV once daily for 5 days followed by [CONTACT_266519]  500 mg/500 mg twice daily 
to complete 7 -10 total days of treatment (N  = 338) or ertapenem  1000 mg IV once daily for 
5 days followed by [CONTACT_266517] 500 mg twice daily and metronidazole 500 mg four 
times daily to complete 7 -10 total days of treatment  (N = 336). Patients with a baseline 
pathogen non- susceptible to ciprofloxacin, but susceptible to amoxicillin/clavulanate, and who 
met criteria for oral step -down took amoxicillin/clavulanate 875 mg/125 mg  twice daily instead 
of ciprofloxacin and metronidazole to complete the 7 -10 total days of treatment.  
Clinical success was seen in 85.5% of patients in the sulopenem group and 90.2% of patients in 
the ertapenem group in the micro- MITT population (treatment difference - 4.7%, 95% CI [ -10.3, 
1.0]); the study thus narrowly missed its stated objective of demonstrating the noninferiority of 
sulopenem to ertapenem in the treatment of cIAI. In all other study populations ‚ÄîITT, MITT, 
CE, and ME ‚Äîthe lower  limit of confidence interval was above -10.0. These findings a re in the 
context of regulatory criteria that vary from - [ADDRESS_324405]-of- care, 
amoxicillin/clavulanate , in an era of significant antibacterial resistance to multiple standard -of-
care oral antibiotics . The activity of oral sulopenem will be compared to amoxicillin/clavulanate  
in patients with organisms susceptible to amoxicillin/clavulanate , to provide a quantitative 
estimate of relative activity established by [CONTACT_105] -inferiority testing as well as in patients with 
organisms tha t are resistant to amoxicillin/clavulanate  through superiority testing. Further 
analyses examining outcomes in the as -randomized populations will attempt to define the 
relative activity of these two drugs without the benefit of culture results, the utility  of which may 
be dependent on the actual findings in the different sub-populations. IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 28 of 84  
Rationale for amoxicillin/clavulanate as the comparator:  
Amoxicillin /clavulanate was chosen as the comparator because it is an approved antibiotic for 
the indication of UT I [Augmentin USPI], it is  listed as a treatment option in the IDSA Treatment 
Guideline [Gupta 2011], and as a Œ≤ -lactam antibiotic, it is likely to have a similar effect to 
sulopenem on the urogenital microbiome, thus allowing for a fair comparison of effic acy.  The 
dose of amoxicillin/clavulanate (875 mg/125 mg PO twice daily) was chosen to justify the use of 
amoxicillin/clavulanate CLSI breakpoints for uncomplicated urinary tract infection (M100 
Performance Standards for Antimicrobial Susceptibility Testing, 32nd edition ). See Appendix 1  
for further details on the rationale for using amoxicillin/clavulanate as the comparator.  
1.2.1 Safety data  
[IP_ADDRESS]  Sulopenem etzadroxil (PF-03709270; oral prodrug)  
Pre-clinical data  
The non- clinical program to assess toxicity of sulopenem etzadroxil  consisted of acute oral and 
repeat -dose toxicity studies, safety pharmacology studies, genetic toxicity assessments, and 
reproductive development toxicity studies in rats and rabbits.  Fol lowing oral administration of 
sulopenem etzadroxil  in rats and monkeys, circulating concentrations of sulopenem etzadroxil  
were variable and minimal or below limits of quantitation, whereas significant levels of 
sulopenem and 2- EBA were present in whole blood. Effects observed in rats and monkeys from 
the repeat dose toxicology studies were generally consistent with those expected from the active moiety sulopenem. The No -Observed -Adverse- Effect -Level ( NOAEL ) in the rat is 100 
mg/kg with a C
max of 1.90 ¬µg/mL and AUC of 7.24 ¬µg‚Ä¢h/mL for sulopenem, and the NOAEL in 
the monkey is 50 mg/kg with a C max of 4.63 ¬µg/mL and an AUC of 11.1 ¬µg‚Ä¢h/mL for 
sulopenem, respectively. Sulopenem etzadroxil  was negative in mutagenicity and in vivo 
clastogenicity tests but po sitive for clastogenic activity in human lymphocytes. Sulopenem 
etzadroxil  had no effects on male and female rat fertility and early embryonic development and 
was not teratogenic to rats or rabbits. Developmental toxicity was observed in both rats and 
rabbits with the NOAEL being 100 mg/kg and 5 mg/kg, respectively, at doses where maternal 
toxicity was also observed.  
Previous human experience  
The sulopenem etzadroxil  studies have investigated the pharmacokinetics, safety, and 
tolerabi lity of single oral doses ranging from [ADDRESS_324406] also been investigated.  
Single doses of sulopenem etzadroxil  of 400 mg, 600 mg, 1000 mg, and 2000 mg produced an 
approximately linear increase in sulopenem mean exposure. The apparent terminal half -life of 
sulopenem was generally dose independent and ranged from 0.76 hours to 1.10 hours.  
Mean time to observed maximum concentration (T max) was on average 1 hour for all doses. 
Neither sulopenem etzadroxil  nor formic acid has been detected in either plasma or whole 
blood following dosing with sulopenem etzadroxil . In addition, the levels of 2- EBA were 
much lower (~1/20) than sulopenem concentrations. During the administration of multiple IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 29 of 84 doses of  sulopenem etzadroxil  for 10 days due to the short half -life of sulopenem etzadroxil  
there is no accumulati on on Day 10 of dosing.  Sulopenem etzadroxil  doses of 2000 mg 
produced a mean sulopenem C max of 4.7 ¬µg/mL and a mean AUC last of 13.1 h‚Ä¢¬µg/mL. 
Sulopenem systemic exposure parameters (C max and AUC last) following sulopenem etzadroxil  
single doses ranging from [ADDRESS_324407] of food (high fat meal) on the PK of sulopenem, given  as sulopenem 
etzadroxil  orally. The mean AUC inf and C max increased 69% and 13.5% respectively, with a 
longer mean time above MIC of 1 ¬µg/ mL (1.91 hours).  Mean t 1/2 was similar between the fed 
and fasted states (0.98 -1.14 hr).  
The concentrations of radioactivity in plasma and whole blood, the excretion of radioactivity 
and the metabolic pathways of [14C] sulopenem etz adroxil have been determined in healthy 
male volunteers (N = 4) following single oral solution (2000 mg) administration. The majority of the radioactivity was excreted in the urine and feces (40.8 and 44.3% respectively). Total mean recovery of radioactivi ty ranged from 80.2 to 95%.  
Overall sulopenem etzadroxil  was well tolerated in the P hase [ADDRESS_324408] common 
adverse events occurring in the program were diarrhea and abnormal urine odor.  Of note, the 
incidence of loose stools/diarrhea was significantly lower in patients dosed with food.  
Oral sulopenem was safe and well -tolerated across the Phase 3 program in patients with uUTI 
(Study IT001- 301), cUTI (Study IT001- 302), and cIAI (IT001- 303) (see details for individual 
studies above).  
[IP_ADDRESS]  Sulopenem (CP -70,429; Intravenous) 
Preclinical data  
In non- clinical evaluations of intravenous administration of sulopenem , the NOAEL in the 
2-week toxicity study in rats was 200  mg/kg with extrapolated AUC (0-tlast)  of 50 ¬µg‚Ä¢h/mL.  The 
NOAEL was based on increases in kidney and liver weights, erythema, and salivation at 800 mg/kg.  
The NOAELs in the 4 -week toxicity studies in rats and monkeys were both 60 mg/kg.  In rats, 
the NOAEL was based on a slight decrease in RBC parameters and increases in liver, kidney, 
and cecum weights at ‚â• 60 mg/kg.  In monkeys, the NOAEL was based on a decrease in RBC 
parameters and increased bilirubin at 200  mg/kg.  
The NOAELs in the 3 -month studies were 120 mg/kg in the rat; AUC
(0-tlast)  of 29.2  ug‚Ä¢hr/mL 
(AUC (0-tlast)  represents 0 -2 h), and 60  mg/kg in the monkey; AUC (0-tlast)  of 49.2  ug‚Ä¢hr/mL; 
(AUC (0-tlast)  represents 0 -8 h).  The NOAEL in rats was based on adverse effects on body weight 
and food consumption, and slight decreases in RBC parameters at 600 mg/k g.  The NOAEL in 
monkeys was based on a positive Direct Coombs test result, decreases in RBC parameters, 
increased bilirubin, moribundity in 2 animals, bone marrow hyperplasia, and soft stools at 
200 mg/kg.  
No change in heart rate or QTc was observed in a single -dose cardiovascular safety 
pharmacology study in anesthetized dogs up to 300 mg/kg, yielding an average blood level of 
258 ¬µg/mL (total). Similarly, no change in heart rate or QTc was observed in the cardiovascular 
study in telemetry -implanted monkeys at 1000  mg/kg, yielding a blood concentration of 
2270 ¬µg/mL (total).    IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -[ADDRESS_324409] on the hERG potassium channel, sulopenem 
inhibited the hERG current by [CONTACT_3450] 50% at the maximum concentration of 300 ¬µM 
(105 ¬µg/mL; free). There were no changes in action potential duration in the in vitro  Purkinje 
fiber assay at concentrations up to 300 ¬µM (105  ¬µg/mL; free).   
Previou s human experience 
In healthy adults, intravenous sulopenem doses up to 1000 mg BID were studied in 3 small 
Phase  1 studies (two in Japan and one in the US) [ Foulds 1991] in the early 1990‚Äôs; sulopenem 
was well tolerated.  The mean C max and AUC inf were 61.5  ¬µg/mL and 51.9 ¬µg‚Ä¢h/mL, 
respectively for a single 1000 mg dose infused over 30 minutes in the Japanese study.  The mean 
Cmax and AUC inf were 69.8  ¬µg/mL and 54.1  ¬µg‚Ä¢h/mL, respectively, for a single 1000 mg dose 
infused over 10  minutes in the US study.  
Doses of 400 mg, 800 mg,  1600 mg, 2400 mg and 2800 mg of IV sulopenem  were evaluated in a 
single dose ascending study, and doses of 800 mg infused over 3 hours, 1200 mg infused over 1 
hour, 1200 mg infused over 2.5 hours, 1600 mg infused over 1.5 hours for 14 days and 2000 mg 
infused over 1.5 hours for 7 days were evaluated in a multiple dose study in healthy volunteers (8 
subjects in each dose group). There were no deaths or serious adverse events (SAEs) in either study. One subject who received 1200 mg IV BID was discontinued on Day 4 from study drug 
therapy due to an adverse event (AE) of mildly increased troponin (0.107 ng/mL [normal limit <0.04 ng/mL]); the AE was reported to be resolved on Day 8. The most frequently reported AEs 
were gastrointestinal events (nausea, vomiting) . Severe AEs included nausea and vomiting and 
were reported only in the highest dose groups (>2000 mg), indicating that MTD had been 
reached. All AEs in the lower dose groups (<2000 mg) were considered mild to moderate in 
severity. No clinical laboratory abnormalities occurred that were considered to be clinically 
significant by [CONTACT_093]. There were no vital signs or ECG changes (including QTc 
interval changes) of clinical concern.  
Pharmacokinetic analysis revealed a dose proportional increase in C
max and AUC last. The mean 
t ¬Ω remained constant over the dose range. Following a 1-hour intravenous infusion, all doses 
higher than 400 mg produced mean concentrations above 1.0 Œºg/mL for > 3.3 hours, allowing for a twice daily dosing and potentially a single daily dose with a longer infusion duration.  
IV sulopenem was also investigated in four Phase  2 clinical efficacy studies in Japan in the early 
1990s.  Over f ourteen hundred patients with hospi[INVESTIGATOR_266489] 250 or 500  mg BID dosing regimens of IV sulopenem for 3 to 14  days.   
Complete information on oral sulopenem etzadroxil  and IV sulopenem  is available in the 
Investigator‚Äôs Brochure.  
1.2.[ADDRESS_324410] 50 years has  resulted in the 
developm ent of microbial resistance to these agents among clinically  important bacteria. This 
resistance commonly takes the form of √ü- lactamase production , development of porins  or 
alterations in penicillin -binding proteins (PBPs). Such mechanisms have reduced the  clinical  
utility of frequently prescribed √ü- lactams such as amoxicillin, amoxicillin plus clavulanate  (a √ü-
lactamase inhibitor), and cephalosporins. The issue of resistance continues to drive the  search for IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -[ADDRESS_324411] resistant pathogens.  Nowhere is the 
importance of resistance more evident than among agents of the √ü- lactam  family.  
For Escherichia coli , ampi[INVESTIGATOR_104514] ‚â•50% in high -risk populations, and 
resistance to third generation ceph alosporins is now being seen in certain  areas. Only through the 
recognition of factors associated with increasing resistance and the  mechanisms responsible can 
strategies be designed for minimizing √ü- lactam resistance. Quinolone resistance and resistance t o 
trimethoprim- sulfamethoxazole among Escherichia coli  is now > 20% in the [LOCATION_002] ; 
likewise, nitrofurantoin resistance among Enterobacterales is near or above 20% .   
As antibiotic resistance leads to increased costs of treatment, increased morbidity as well as  
increased mortality, there is an unmet urgent medical need for antimicrobial agents that can  be 
utilized in serious hospi[INVESTIGATOR_104515], especially agents that can be delivered 
orally. 
The penems are considered to exhibit  advantages to the √ü- lactam class as they possess good  
antibacterial activity against pneumococci and G ram-negative pathogens commonly responsible 
for a wide range of community and hospi[INVESTIGATOR_266490]  √ü-lactamases.  
Sulopenem has in v itro activity against many common hospi[INVESTIGATOR_104517], including  extended 
spectrum √ü -lactamase (ESBL) producing , and/or quinolone non-susceptible gram -negative 
pathogens (except  Pseudomonas spp., and some other non- lactose fermenting gram -negat ive 
rods), and anaerobes.  
Rationale for probenecid  
Probenecid is known to increase plasma levels of weak organic acids such as penicillins, 
cephalosporins, and other Œ≤ -lactam antibiotics, including penems, by [CONTACT_259489].   Probenecid has been used safely with other Œ≤ -lactam antibiotics, to 
either reduce dose or dosing frequency of Œ≤ beta- lactams when used to treat infectious diseases in 
human beings.   
Probenecid has been shown in an animal dog model to increase the systemic exposure of a 
penem CP -65,207 ( sulopenem is the S -isomer of CP -65,207) by [CONTACT_2902] 2- fold, suggesting a role 
of active renal tubular secretion in drug elimination. Findings from a previous clinical pharmacokinetic study indicate that renal clearance accounts for a significant proportion 
(approximately 50%) of total clearance of sulopenem in healthy volunteers suggesting that 
probenecid could increase exposure and thus time over MIC for sulopenem .    
In a previous Phase 1 study (A8811007), the use of  [ADDRESS_324412] on the PK of sulopenem.   While the sulopenem AUC was significantly 
higher for the 1000 mg probenecid administration, the %T
free >MIC was very similar, as 
anticipated, suggesting that the 500 mg of probenecid may provide sufficient extension of 
circulating sulopenem to achieve the PKPD objectives.  The combination of  oral sulopenem 
etzadro xil 500 mg and probenecid 500 mg was evaluated in a  recently completed  study, IT001-
101. R esults from this study were consistent with those observed in previous studies.  
Thus, probenecid has the potential to be used as a PK booster with sulopenem etzadroxil , 
optimizing the time over MIC for any given sulopenem dose while minimizing the 
gastrointestinal exposure  of the parent compound and subsequent gastrointestinal adverse events 
such as diarrhea.   IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -[ADDRESS_324413] label for more pharmacology information.  
Rationale for dosing with food  
In a multiple dose (A8811003) study, at higher doses of oral sulopenem etzadroxil , there was  a 
higher rate of gastrointestinal symptoms especially diarrhea in a fasted state.  It has therefore 
been postulated that if the fraction of sulopenem etzadroxil  absorbed and bioavailability of 
sulopenem ( CP-70,429, the active moiety) can be increased, the gastrointestinal toleration and 
pharmacokinetics of the compound can be improved.  
In Study A8811008 there was an increase in relative bioavailability of sulopenem when oral 
sulopenem etzadroxil  was administered in the fed state (~82% increase in mean AUC).  In Study 
IT001-101, oral sulopenem etzadroxil  was evaluated in a fasted and fed state at a dose of 500 mg 
BID. Results from this study indicate that food signif icantly increases bioavailability of 
sulopenem and consequently results in decreased rates of diarrhea.  Therefore, dosing of oral 
sulopenem- etzadroxil with food whenever possible is recommended.  Since adequate target 
attainment appears to be achieved in t he fasted state, an inability to administer the dose with food 
should not preclude dosing.  
1.2.3 Dose Rationale  
Sulopenem etzadroxil  
Doses of oral sulopenem etzadroxil  were chosen by [CONTACT_31577]/PD modeling using a combination of ( 1) 
modeling (Na√Øve Pool analysis) of t he sulopenem effect on net change in colony forming units 
(CFU) over 24 hours of clinically relevant organisms in an immunocompetent mouse thigh infection model , (2) defining targets of percent time above the MIC (T>MIC) for sulopenem 
from this mouse model , and ( 3) population PK modeling using nonlinear mixed effects models , 
generated from  clinical data in  multiple oral sulopenem etzadroxil  Phase 1 studies in healthy 
volunteers.  
Monte Carlo simulations were performed using the human population PK parameters for 
sulopenem etzadroxil  and mean pharmacodynamic parameters from murine thigh infection 
model to determine % target achievement (TA) for the selected doses. A %TA of ‚â•90% was deemed desirable for selecting particular doses. The 500 mg dose of oral sulopenem etzadroxil  
co-administered with 500 mg of probenecid administered twice daily meets the criteria of 
%T>MIC for achieving 1- log kill in bacteria.  
Probenecid  
The maximum tota l daily dose of probenecid will be 1000 mg (500 mg BID) which is within the 
recommended dosage of 2000 mg daily in divided doses.  
Amoxicillin/clavulanate   
The FDA approved (NDA 50 -720/S024) dose of 875 /125 mg oral amoxicillin/clavulanate  
administered twice daily for 5 days for treatment of uncomplicated UTI , per the Augmentin 
USPI , will be used in this study.  This dose was chosen to justify the use of IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 33 of 84 amoxicillin/clavulanate CLSI breakpoints for uncomplicated urinary tract infection ( M100 
Performance Standards for Antimicrobial Susceptibility Testing, 32nd edition ). 
For the full prescribing information for probenecid or amoxicillin/clavulanate , please refer to 
respective local country product labels.  
2 STUDY OBJECTIVES  
 
2.1 Objectives  
Non-infer iority Trial : 
Objective  Estimand/ Endpoint  
Primary:  Primary  Estimand : 
To compare the overall response (clinical and 
microbiologic combined response) at Day 12 
(¬±1 day)/test of cure (TOC) of oral sulopenem 
etzadroxil/probenecid tablets (500 mg/500 
mg) versus oral amoxicillin/clavulanate ( 875 
mg/125 mg) tablets for the treatme nt of 
uncomplicated urinary tract infection in adult women. Endpoint of interest: Overall success 
at Day 12 (¬±1 day)/TOC (clinical and microbiologic combined)  
Intercurrent events: non- susceptibility 
or resistance to 
amoxicillin/clavulanate, use of rescue 
antibiotic, study discontinuation  
Population level summary of variable: Comparison of overall success rates 
between treatment groups  
Secondary:  Secondary  Endpoints : 
To evaluate the clinical efficacy at Day 12 
(¬±1 day)/TOC.  Clinical cure ( resolution of the 
symptoms of uUTI present at trial 
entry and no new uUTI symptoms) at 
Day 12 (¬±1 day)/TOC.  
To evaluate the rate of post -treatment 
asymptomatic bacteriuria at Day 12 (¬±1 
day)/TOC.  Clinical cure ( resolution of the 
symptoms of uUTI present at trial 
entry and no new uUTI symptoms) 
and microbiologic persistence (‚â• 103 
CFU/mL of the baseline uropathogen) 
at Day 12 (¬±1 day)/TOC  
To evaluate the microbiologic efficacy at Day 
12 (¬±1 day)/TOC.  Microbiologic eradication (<103 
CFU/mL of the baseline uropathogen) 
at Day 12 (¬±1 day)/TOC  
To further evaluate the safety profile of oral 
sulopenem etzadroxil/probenecid tablets (500 
mg/500 mg) when used for treatment of uUTI 
in adult women.  Incidence of TEAEs through Day 28 
(¬±2 days); Changes from baseline i n 
clinical laboratory tests at the Day 12 
(¬±1 day) /TOC  visit; Changes from 
baseline in vital signs at the Day 5 (+1 day)/EOT and Day 12 (¬±1 day) /TOC  
visits  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 34 of 84  
 
Additional:  Additional  Endpoints : 
To evaluate the clinical efficacy at Day 5 (+1 
day) and Day 28 (¬±2 days).  Clinical cure ( resolution of the 
symptoms of uUTI present at trial 
entry and no new uUTI symptoms) at 
Day 5 (+1day) and Day 28 (¬±2 days).  
To evaluate the rate of post -treatment 
asymptomatic bacteriuria at Day 5 (+1 day) and Day 28 (¬±2 days).  Clinical cure ( resolution of the 
symptoms of uUTI present at trial entry and no new uUTI symptoms) 
and microbiologic persistence (‚â• 10
3 
CFU/mL of the b aseline uropathogen) 
at Day 5 (+1 day) and Day 28 (¬±2 
days).  
To evaluate the microbiologic efficacy at Day 
5 (+1 day) and Day 28 (¬±2 days).  Microbiologic eradication (<103 
CFU/mL of the baseline uropathogen) at Day 5 (+1 day) and Day 28 (¬±2 
days).  
To eva luate overall response at other relevant 
timepoints  Overall success (clinical and 
microbiologic combined response) at Day 5 (+1 day) and Day 28 (¬±2 days) 
visits  
To evaluate the investigator determined 
clinical response  Investigator determined clinical 
response (clinical success, failure, and 
indeterminate) at Day 5 (+1 day), Day 
12 (¬±1 day)/TOC, and Day 28 (¬±2 
days)  
To evaluate overall success, clinical success, 
and microbiologic success by [CONTACT_266520], clinical success, and 
microbiologic success at Day 5 (+1 
day), Day 12 (¬±1 day)/TOC, and Day 
28 (¬±2 days) by [CONTACT_266521]  
3 STUDY DESIGN  
Study IT001-310 is a prospective, Phase 3, randomized, multicenter, double -blind, double 
dummy, controlled study to compare oral sulopenem to oral amoxicillin/clavulanate  for the 
treatment of patients with uUTI.  Approximately 1966 adult women with uUTI will be 
randomized in a 1:1 fashion to receive either oral sulopenem etzadroxil /probenecid 500 mg/500 
mg twice daily for 5 days or oral amoxicillin/clavulanate  875 mg/125 mg twice daily for 5 days. 
End of Therapy is defined as Day 5 (+ 1 day) . The primary efficacy assessment will be overall 
response (combined clinical and microbiologic response [ success , failure  or indeterminate ]) in 
the micro -MITT, micro-MITT S and micro -MITTR populations on Day 12 (¬± 1 day) /TOC . 
Secondary efficacy assessment s will include the clinical response (success, failure, or 
indeterminate), and microbiologic response ( success [ eradication ], failure [ persistence or 
persistence with increasing MIC ] or indeterminate ) on Day 12 (¬± 1 day) /TOC . See Appendix 2,  
Schedule of Activities Table.  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 35 of 84 3.1 Investigational Study Medications  
Patients will be randomized to receive either a bilayer tablet with sulopenem 
etzadroxil /probenecid 500 mg/500 mg  PO twice daily for 5 days or amoxicillin/clavulanate  875 
mg/125 mg PO twice daily for 5 days.  
Sulopenem etzadroxil treatment group:  The study drug will be supplied as a study kit containing 
one bottle with 10 bilayer tablets containing sulopenem etzadroxil /probenecid 500  mg/500 mg 
and one blister wallet containing  10 amoxicillin/clavulanate placebo capsules . 
Comparator treatment group:  The study drug will be supplied as a study kit containing one blister wallet containing  10 over- encapsulated amoxicillin/clavulanate  875 mg/125 mg tablet s, 
and one bottle with 10 placebo tablets to match sulopenem etzadroxil/probenecid tablets.   
3.2 
Adjunctive Systemic Antibiotics  
None allowed  except as described in Section 5.4.2 .    
3.3    Additional Non-Study Therapy Antibiotics 
For Clostridioides difficile  infections, metronidazole (IV or oral), vancomycin (oral or rectal) , or 
fidaxomicin (oral) may be used in both treatment groups. Patients with a co- infection with a 
gram -positive uropathogen known or suspected to be resistant to study drugs are allowed to  
receive agents with narrow spectrum gram -positive coverage (such as oral linezolid)  at the 
discretion of the investigator . 
[ADDRESS_324414] patients for whom protocol treatment is considered 
appropriate.  All relevant medical and non -medical conditions should be taken into consideration 
when deciding whether a particular patient is suitable for enrollment under this protocol . 
4.1 Inclusion Criteria  
1. Female patients ‚â•18 years of age with ‚â•24 hours and ‚â§96 hours  of urinary symptoms 
attributable to a UTI  
2. Two of the following signs and symptoms of uUTI:  urinary frequency, urinary urgency, 
pain or burning on micturition, suprapubic pain.  
3. A mid -stream urine specimen with:  
a. a machine- read dipstick positive for nitrite AND any positive leukocyte esterase  
OR,  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 36 of 84 b. evidence of pyuria alone as defined by [CONTACT_5640]:  
i. a machine- read dipstick positive for large leukocyte esterase OR  
ii. at least 10 white blood cells per cubic millimeter on microscopic analysis 
of unspun urine OR  
iii. White blood cell count ‚â•10 cells/HPF in the sediment of a spun urine  
4. Has given written informed consent to participate in the study  
4.2 Exclusion Criteria  
1. Presence of signs and symptoms suggestive of acute pyelonephritis defined as: fever 
(temperature > 38¬∞ Celsius), chills, costovertebral angle tenderness, flank pain, nausea, 
and/or vomiting  
2. Receipt of antibacterial drug therapy potentially effective as treatment of uUTI within the prior [ADDRESS_324415] on outcome 
evaluations in patients with uUTI, including analg esics (e.g., non -steroidal anti-
inflammatory drugs, aspi[INVESTIGATOR_248], paracetamol etc.), phenazopyridine, and cranberry products . 
Note: Patients can be included if these medications were previously taken and have 
ceased at the time of Screening onward.    
4. Any anatomical abnormality of the urinary tract, including surgically modified urinary 
tract anatomy, and obstructive uropathy due to nephrolithiasis, stricture, tumor, or 
fibrosis 
5. Ongoing urinary retention  
6. Neurogenic bladder  
7. Current resident of a long- term care facility  
8. Instrumentation of urinary tract in the previous [ADDRESS_324416]  
11. Current urine culture, if available while eval uating eligibility, that is positive for more 
than 2 microorganisms regardless of colony count (contaminated), or confirms a fungal  
UTI 
12. Receiving hemodialysis, hemofiltration, peritoneal dialysis, or had a renal transplant  
13. Immunocompromised as evidenced by [CONTACT_39132]:  
a. Known HIV positive, with either a recent (in the past 6 months) AIDS -defining 
condition or a CD4 + T lymphocyte count <200/mm
3  
b. Known neutropenia (defined as absolute neutrophil count <1000 cells/mm3) IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 37 of 84 c. Systemic or hematological malignancy requiring chemotherapeutic or 
radiation/immunologic interventions within 6 weeks prior to randomization or 
anticipated to begin prior to completion of study 
d. Immunosuppressive therapy, including maintenance corticosteroid therapy (>40 mg/day equivalent prednisolone for 5 days or more in the 30 days prior to 
randomization) 
14. Known liver function abnormalities as defined by [CONTACT_266509]:  
‚Ä¢ ALT or AST > 3x upper limit of normal, and/or  
‚Ä¢ Total bilirubin > 2x upper limit of normal  
15. Females of child -bearing potential who are unable to take adequate contraceptive 
precautions (refer to Sections  4.4 and 4.5), have a positive pregnancy test result within 24 
hours of study entry, are otherwise known to be pregnant, or are currently breastfeeding 
16. Poorly controlled Diabetes mellitus, including the presence of ketoacidosis and 
hyperosmolar hyperglycem ia 
17. History of seizures  
18. History of blood dyscrasias  
19. History of uric acid kidney stones  
20. Acute (current) gouty a rthritis  
21. Concomitant administration of valproic acid  
22. History of allergy or hypersensitivity to carbapenems, Œ≤ -lactams or probenecid, as 
formulated with their excipi[INVESTIGATOR_840]  
23. Unlikely to survive the 4- week study period or has a rapi[INVESTIGATOR_266487], including septic shock, associated with a high risk of mortality  
24. The use of any other investigational drug in the [ADDRESS_324417] of care, 
prior to obtaining informed consent, may be used to assess eligibility for enrollment into study and/or for baseline urine culture.  
4.3 
Randomization Criteria  
Patients will be r andomized in a 1:1 ratio to oral sulopenem versus oral amoxicillin/clavulanate  
using an IW RS into the study provided they have satisfied all patient selec tion criteria.   
4.[ADDRESS_324418] agree to be 
strictly abstinent from sexual intercourse with any individual of the opposite sex, or to follow the following instructions  for contraception.  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 38 of 84 4.5 Women of Child-Bearing Potential  
If the patient is a woman of childbearing potential  (women of child- bearing potential 
and peri -menopausal women include females <50 years of age or those ‚â• [ADDRESS_324419] -menopausal [ amenorrheic] for < 2  years) , and not practicing 
abstinence, that patient is required to simultaneously use [ADDRESS_324420] of five: 
1. A barrier (condoms, diaphragm or cervical cap) with spermicide;  
2. A second, different barrier method (condoms, diaphragm or cervical cap);  
3. Oral or similar contraceptive, which includes, but is not limited to: injectable, implanted , or 
patch hormone therapy, and intrauterine device (IUD);  
4. Documented surgical sterilization at least 4 weeks prior to baseline; 
5. Partner vasectomy at least [ADDRESS_324421] Study Visit. Within these limits, the specific forms of contraception employed are left to the discretion of the patient, and/or the principal investigator, and/or the patient‚Äôs physician and documented in source . 
5 STUDY TREATMENTS  
5.1 Allocation to Treatment 
This is a randomized , double-blind, double dummy, controlled study comparing oral sulopenem 
with oral amoxicillin/clavulanate  in the treatment of uUTI.  Approxima tely 1966 patients will be 
randomized to receive either oral sulopenem twice daily for 5 days or oral 
amoxicillin/clavulanate  twice daily for 5 days in a 1:[ADDRESS_324422] the IWRS  to obtain the 
study treatment assignment and dispense therapy accordingly. The IWRS will associate that patient with the next available treatment on the randomization schedule.  The IWRS will then 
give the investigative site information which corresponds to study medication tha t has been 
previously shipped to the site and is in the site‚Äôs inventory ready to be dispensed. A patient is considered randomized when the site personnel  receive the treatment assignment associated with 
the patient entered into the IWRS.  
5.2 
Drug Supplies  
5.2.1 Formulation and Packaging 
Sulopenem etzadroxil /probenecid treatment group:  The study drug will be supplied as a study 
kit containing one bottle with 10 bilayer tablets containing sulopenem etzadroxil /probenecid 500 
mg/500 mg and one blister wallet containing  10 amoxicillin/clavulanate  placebo  capsules. 
Patients found to have pathogens isolated from urine cultures that are resistant to 
amoxicillin/clavulanate or carbapenems, may be allowed to continue on study drug therapy to 
complete the 5 -day duration of treatment based on clinical response and investigator judgement, 
and are not required to receive alternative antibiotic therapy.  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 39 of 84 Comparator treatment group:  The study drug will be supplied as a study kit containing one 
blister wallet containing  10 over- encapsulated amoxicillin /clavulanate 875 mg/125 mg tablets , 
and one bottle with 10 placebo tablets to match sulopenem etzadroxil/probenecid tablets.   
All supplies packed and labeled will be formally released in accordance with both Good 
Manufacturing Practice (GMP) and Good Clinical Practice (GCP) guidelines.  
5.2.2 Preparation and Dispensing 
All kits  of study drug will be pr ovided to the study site by [CONTACT_266522]. Dispensing of 
study medication will be done and documented in accordance with the treatment schedule as 
outlined in the study protocol.  Written dispensing instructions will be provided to each study site 
in a study pharmacy manual.     
5.2.3 Administration  
Patients  randomized to the sulopenem treatment group will take one sulopenem 
etzadroxil /probenecid tablet  and one  placebo capsule twice daily for 5 days and those 
randomized to the amoxicillin/clavulanate treatment group  will take one over -encapsulated 
amoxicillin/clavulanate tablet and  one placebo tablet  twice daily  for 5 days  (10 doses total over a 
5-day period; if Dose 1 is taken in the evening of Day 1, Dose 10 will be taken in the morning of 
Day 6) . The first dose of  each medication will be administered under the supervision of study 
site personnel  to help ensure compliance with dosing directions . 
Study drug administration will be documented in accordance with the Pharmacy Manual.  
Dosing with food:   
Food significantly increases bioavailability of sulopenem and consequently results in decreased 
rates of diarrhea. Therefore, dosing of oral sulopenem  with food whenever possible is 
recommended.  Since adequate target attainment appears to be achieved in the fasted state, an 
inability to administer the dose with food should not preclude dosing.  
Amoxicillin and clavulanate are well absorbed from the gastrointestinal tract after oral 
administration. Dosing in the fasted or fed state has minimal effect on the pharmacokinetics  of 
amoxicillin. While amoxicillin/clavulanate can be given without regard to meals, absorption of clavulanate when taken with food is greater relative to the fasted state. Therefore, dosing of oral 
amoxicillin/clavulanate with food whenever possible is al so recommended.  
5.2.4 Compliance 
All patients  should be informed that compliance with taking all oral medication as instructed is 
imperative.  
Patients  will be asked to bring all study medication containers  (used and unused) to the next 
scheduled study visit for drug accountability. The total amount of oral dosing completed 
(determined by [CONTACT_266523] ) will be recorded in the 
IWRS /EDC systems .  
A study- specific diary will be provided to every patient to capture compliance with study 
medications.  
A urine sample will be collected and frozen at the Day 5 visit which can be used to confi rm 
compliance, safety , or efficacy asses sments . IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -[ADDRESS_324423]/designee, will ensure that all 
investigational products are stored in a secured area, under recommended storage conditions , and 
in accordance with applicable regulatory requirements.  To ensure adequate records, the IWRS 
will be used to document site standard accountability.   
At the end of the study, Iterum Therapeutics will provide instructions as to disposition of any 
unused investigational product including oral sulopenem and amoxicillin/clavulanate .  If Iterum 
Therapeutics authorizes destruction at the study site, the investigator must ensure that the materials are destroyed in compliance with applicable environmental regulations, institutional 
policy, and any special instructions provided by [CONTACT_104536].  Destruction must be 
adequately documented.  
5.4 
Concomitant Medication(s), Adjunctive Therapy, and Non -drug Therapy  
5.4.1 Concomitant Medications  
Any medication taken by [CONTACT_266524], other than study drug, is considered 
concomitant medication.  All concomitant medications from Baseline (Day  1) through the Fina l 
Visit must be recorded in the patient's source record and on the C ase Report F orm (CRF) . 
At each visit, the investigator/site designee  will obtain information on any therapeutic 
interventions (e.g.,  drug therapy, surgery, etc .) provided.  The use of any other investigational 
drug is prohibited, and patients may not participate in any other studies involving marketed 
products concomitantly while in this study.   
The use of other (non- antibacterial) medications should be limited to those essential for the care 
of the patient.  All medications required by [CONTACT_104564] , and any 
drugs that may be required for emergency treatments , must be recorded on the CRF .  Of note, the 
use of medications to alleviate UTI symptoms (such as analgesics  [e.g., non-steroidal anti-
inflammatory drugs, aspi[INVESTIGATOR_248], paracetamol  etc.], phenazopyridine or cranberry products) is 
prohibited until after the Day 12 (¬± 1 day) /TOC  visit. 
5.4.2 Adjunctive Systemic Antibiotics (Rescue  Therapy) 
In general, adjunctive systemic antibiotics are not allowed  for patients  enrolled in the study.  At 
any time during the study period, and at the discretion of the principal investigator (PI), 
additional antibiotics ‚Äîoral or IV, as appropriate ‚Äîcan be prescribed as rescue therapy, e.g., in 
the event of worsening signs and symptoms of uUTI, or if the patient develops fever and/or flank pain suggestive of upper urinary tract involvement.  In the event that rescue therapy is prescribed, 
patient symptoms will be collected as an unscheduled event; such patients will be considered as failures  and will be asked to still complete all  protocol- specified assessments  through the F inal 
Visit.  Use of adjunctive antibiotics without clinical symptoms is strongly discouraged.  
5.4.3 Additional Non- Study Therapy Antibiotics  
Concomitant systemic antibacterials are prohibited durin g the study, up to the Day 28 (¬± 2 days) 
visit, with the following exceptions:  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 41 of 84 ‚Ä¢ For Clostridioides difficile  infections, metronidazole (IV or oral), vancomycin (oral or 
rectal) , or fidaxomicin (oral) may be used in both treatment groups. The Sponsor will not 
provide therapy for Clostridioides difficile  infections . 
‚Ä¢ Patients with a co -infection with a gram -positive uropathogen known or suspected to be 
resistant to study drugs are  allowed to receive agents with narrow spectrum gram -positive 
coverage (such as oral linezolid)  at the discretion of the investigator . The Sponsor will 
not provide therapy for co- infection with a g ram-positive uropathogen resistant to study 
drugs.  
6 STUDY PROCEDURES  
6.1 Screening (Day -1) - Within [ADDRESS_324424] Dose 
The investigator (or an appropriate delegate at the investigator site) will obtain written informed 
consent from each patient prior to the initiation of any study related activities.  
Urine s amples, including results from urine tests, collected as part of routine standard of care, 
prior to obtaining informed consent, may be used to assess eligibility for enrollment into study 
and/or for baseline urine culture.  
The following screening procedure s will be performed  prior to randomization and study drug 
administration  (Screening and Day 1 Visit will typi[INVESTIGATOR_266491]) : 
‚Ä¢ Obtain signed informed consent  
‚Ä¢ Review d emographics and medical history  
‚Ä¢ Review eligibility criteria  
‚Ä¢ Review previous drug and non- drug treatments (defined as within the prior 30 days)  
‚Ä¢ Review concomitant medications  
‚Ä¢ Review adverse events occurring after signing the ICF  
‚Ä¢ Targeted  physical examination (including general appearance, examination of heart, 
lungs , abdomen, and extremities)  
‚Ä¢ Vital signs (temperature, blood pressure, pulse rate, respi[INVESTIGATOR_697]) , height and weight  
‚Ä¢ Perform urine pregnancy test on women of child- bearing potential, including peri -
menopausal women, and confirm negative result .  
‚Ä¢ Women of  child -bearing potential and peri -menopausal women include females 
<50 years of age or those ‚â• [ADDRESS_324425] -menopausal 
[amenorrheic] for < 2  years  
‚Ä¢ Collect urine for urinalysis and urine culture and susceptibility  
‚Ä¢ Blood for laboratory testing including hematology and chemistry studies  
‚Ä¢ Banked serum and urine for retrospective safety and efficacy assessments  
 
 
To prepare for trial participation, patients will be instructed on the use of Life style Guidelines 
and Concomitant Medications.  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 42 of 84 6.2 Treatment Period  
For the study period described below, where multiple procedures are scheduled at the same time 
point(s) relative to dosing, the following chronology of events should be adhered to, where possible. 
‚Ä¢ Blood pressure/pulse rate: obtain prior to blood specimen collection 
 
6.2.1 Day 1 
‚Ä¢ Review concomitant  medications and adverse events if Day 1 visit not on same day as 
Screening/Day -1 visit  
‚Ä¢ Confirm eligibility if Day 1 visit not on same day as Screening/Day - 1 visit  
‚Ä¢ Randomize patient  
‚Ä¢ Provide patient  daily dosing diary along with instructions on how to complete  
‚Ä¢ Have patient  complete patient symptom assessment questionnaire  
‚Ä¢ Administer the study medication as described in Section  5.2.3  
 
 
6.2.2 Day 5 (+ 1 day) ( End of Treatment/ EOT)  
‚Ä¢ Targeted physical examination, if required, based on patient‚Äôs symptoms  (as 
determined by [CONTACT_093])  
‚Ä¢ Vital signs (temperature, blood pressure, pulse rate, respi[INVESTIGATOR_697])  
‚Ä¢ Bank urine for retrospective assessments  
‚Ä¢ Collect urine for urinalysis  and urine culture and sensitivity  
‚Ä¢ Review concomitant medications  
‚Ä¢ Assess symptoms by [CONTACT_266525] a non- leading question such as ‚ÄúHow do you feel?  
‚Ä¢ Confirm and document study medication compliance by [CONTACT_21173][INVESTIGATOR_266492]  
‚Ä¢ Collect patient  daily dosing diary and review for completeness  
‚Ä¢ Have patient complete patient symptom assessment questionnaire  
‚Ä¢ Investigator Assessment of Clinical Response (Section  7.2.4 ) 
6.3 Follow-up Period  
6.3.1 Day 12 (¬± 1 day) ( Test of Cure/ TOC)  
‚Ä¢ Targeted physical examination, if required, based on patient‚Äôs symptoms  (as 
determined by [CONTACT_093])  
‚Ä¢ Vital signs (temperature, blood pressure, pulse rate, respi[INVESTIGATOR_697])  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 43 of 84 ‚Ä¢ Blood for laboratory testing (including hematology and chemistry studies)  
‚Ä¢ Bank serum and urine for retrospective safety and efficacy assessments  
‚Ä¢ Collect urine for urinalysis  and urine  culture and sensitivity   
‚Ä¢ Review concomitant medications  
‚Ä¢ Assess symptoms by [CONTACT_266526] a non- leading question such as ‚ÄúHow do you feel?  
‚Ä¢ Have patient  complete patient symptom assessment q uestionnaire 
‚Ä¢ Investigator Assessment of Clinical Response (Section  7.2.4 ) 
6.3.2 Day 28 (¬± 2 days) ( Final Visit/FV)   
‚Ä¢ Targeted physical examination, if required, based on patient‚Äôs symptoms  (as 
determined by [CONTACT_093])  
‚Ä¢ Perform urine pregnancy test on women of child -bearing potential, 
including peri -menopausal women, and confirm negative result . 
Women of child- bearing potential and peri -menopausal women 
include females <50 years of age or those ‚â• [ADDRESS_324426] -menopausal [amenorrheic] for < 2  years  
‚Ä¢ Collect urine for urinalysis , urine culture and sensitivity 
‚Ä¢ Review concomitant medications  
‚Ä¢ Assess symptoms by [CONTACT_266525] a non- leading question such as ‚ÄúHow do you feel?  
‚Ä¢ Have patient  complete patient symptom assessment questionnaire  
‚Ä¢ Investigator Assessment of Clinical Response ( Section  7.2.4) 
6.4 Premature Discontinuation 
‚Ä¢ Targeted physical examination, if required, based on patient‚Äôs symptoms  (as 
determined by [CONTACT_093])  
‚Ä¢ Vital signs (temperature, blood pressure, pulse rate, respi[INVESTIGATOR_697])  
‚Ä¢ Blood for laboratory testing including hematology and chemistry studies  
‚Ä¢ Perform urine pregnancy test on women of child- bearing potential, 
including peri -menopausal women, and confirm negative result  
o Women of child- bearing potential and peri -menopausal women 
include females <50 years of age or those ‚â• [ADDRESS_324427] -menopausal [amenorrheic] for < 2  years  
‚Ä¢ Collect urine for urinalysis  and urine culture and sensitivity 
‚Ä¢ Review concomitant medications  
‚Ä¢ Assess symptoms by [CONTACT_266525] a non- leading question such as ‚ÄúHow do you feel?  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 44 of 84 ‚Ä¢ Confirm and document study medication compliance by [CONTACT_21173][INVESTIGATOR_266492]  
‚Ä¢ Have patient  complete patient symptom assessment questionnaire 
‚Ä¢ Investigator Assessment of Clinical Response ( Section  7.2.4) 
6.[ADDRESS_324428]  the patient to return for 
all protocol -specified assessments,  if possible, and follow -up with the patient regarding a ny 
unresolved AEs through the final visit.  
For patients who withdraw from the study early, a Premature Discontinuation visit should be 
performed within 3 calendar days  after decision to discontinue  (Section  6.4 and no further visits 
are required . 
If the patient withdraws  from the study, and also withdraws consent for disclosure of future 
information, no further study- specific evaluations should be performed, and no additional data 
should be collected.  The sponsor may retain and continue to use any data collected before such 
withdrawal of consent. 
7 ASSESSMENTS  
7.1 Safety 
7.1.1 Physical Examination  
A targeted physical examination will be performed at Baseline (including general appearance, 
examination of heart, lungs, abdomen, and extremities).  A targeted physical exam may be 
conducted at any visit to address patient‚Äôs symptoms if needed  (as determined by [CONTACT_1275]). 
7.1.2 Vital Signs ( Temperature, Blood Pressure, Pulse  Rate, Respi[INVESTIGATOR_259477])  
Vital signs are performed at Baseline, Day 5 (+ 1 day) , Day 1 2 (¬± 1 day)/TOC , or P remature 
Discontinuation. Blood pressure will be measured and recorded to the nearest mm Hg.  All blood pressure 
measurements should be taken at rest .  The same size blood pressure cuff should be used to 
measure blood pressure each time.  When the timing of these measurements coincides with a blood collection, blood pressure and pulse rate are to be obtained first.  Temperature may  be 
measured as an oral, rectal, tympanic (ear) or temporal temperature.  
7.1.3 Clinical Laboratory Assays  
The following laboratory parameters will be measured :  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 45 of 84 ‚Ä¢ Hematology: Complete blood count (CBC), including white blood cell (WBC) and 
differential c ounts; at Baseline, Day 12 (¬± 1 day) /TOC  or P remature Discontinuation 
‚Ä¢ Serum Clinical Chemistry: AST, ALT, GGT, alkaline phos phatase, albumin, total and direct 
bilirubin, BUN or urea, creatinine, Na+, K+, Cl -, total CO2 (Bicarbonate), glucose, high 
sensitivity C-reactive protein (CRP) and LDH at Baseline, Day 12 (¬± 1 day) /TOC  or 
Premature Discontinuation. 
‚Ä¢ Urinalysis  and urine culture  and sensitivity at Baseline, Day 5 (+ 1 day) , Day 12 (¬± 1 
day)/TOC  and Day 28 (¬± 2 days) or Premature Discontinuation.  
ÔÉò Susceptibility results of pathogens to amoxicillin /clavulanate and carbapenems from 
cultures obtained at Screening, EOT, and TOC should not be reported to 
sites/investigators until after the TOC visit, unless requested by [CONTACT_9532] [INVESTIGATOR_266493] , so as not to influence the investigator‚Äôs decision 
to prescribe a rescue antibiotic in the case of pres ence of a non- susceptible pathogen. 
‚Ä¢ Urine pregnancy test performed at the site for women of child- bearing potential, including 
peri-menopausal women; at Baseline and Day 28 (¬± 2 days)) or Premature Discontinuation. 
ÔÉò Women of child- bearing potential and peri -menopausal women include females <50 
years of age or those ‚â• [ADDRESS_324429] -menopausal [amenorrheic] 
for < 2  years  
‚Ä¢ Serum pregnancy test performed by [CONTACT_266527]  
‚Ä¢ Serum and urine samples will be  banked for retrospective safety and efficacy analyses as  
needed  at Baseline, Day 5 [(+ 1 day); urine only],  and Day 12 (¬± 1 day) /TOC . Banked 
serum and urine samples may be stored up to [ADDRESS_324430] 
results occurring during the study will be repeated at appropriate intervals until they return either to baseline or to a level deemed acceptable by [CONTACT_104568].    
7.2 
Efficacy 
7.2.1 Overall Response  
Overall  Response (at a given Visit) is assessed using the definitions listed below:  
A patient will be defined as a success  if the following criteria are met (programmatically, based 
on the data on the eCRF) : 
‚Ä¢ The patient is alive  
‚Ä¢ The patient has received no rescue therapy for uUTI  
- If an antibiotic  active against the urinary tract pathogen is given for other reasons, then 
the patient will be considered indeterminate  
‚Ä¢ The patient has resolution of the symptoms of uUTI present at trial entry and no new uUTI 
symptoms (based on the Patient Symptom Assessment Questionnaire)  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 46 of 84 - Baseline symptoms associated with another known condition (e.g., overactive 
bladder) do not need to be  resolved.   
‚Ä¢ Urine culture demonstrates <103 CFU/mL of the  baseline uropathogen based on results of 
quantitative cultures performed on collected urine specimens.  
Results of susceptibility testing to differentiate between pathogens isolated at baseline and follow- up visits will be used in a sensitivity analysis to  be specified in the SAP; whole 
genome sequencing (WGS) of isolated organisms may be performed if needed and results will 
be used in a sensitivity analysis to be specified in the  SAP.  
All other patients will be considered as failures  unless data are unavailable to determine if the 
patient is a confirmed overall success or a failure. In this case, the patient will be considered as 
having an indeterminate response.  Patients with an indeterminate response are included in the 
denominator for determination of the response rate.  
7.2.2 Microbiologic 
Microbiologic Response is assessed using the definitions listed below:  
Microbiological 
response  Definition  
Success  The urine cu lture demonstrate s <103 CFU/mL of the baseline 
uropathogen (also referred to as eradication) at the time -point of 
analysis, i.e., Day 5 ( + 1 day) , Day 12 (¬± 1 day) /TOC , or Day 28 
(¬± 2 days ) visit  
Persistence  A uropathogen present at baseline  grew at ‚â• 103 CFU/mL at the 
time-point of analysis, i.e.,  Day 5 ( + 1 day) , Day 12 (¬± 1 
day)/TOC , or Day 28 (¬± 2 days ) visit 
Persistence with 
increasing MIC  A urine culture taken after at least 2 full days of treatment grew 
‚â•103 CFU/mL of the baseline  uropathogen and displayed ‚â•4-
dilutions higher MIC , as compared to bas eline, to study drug 
received at the time -point of analysis, i.e., Day 5 ( + 1 day) , Day 
12 (¬± 1 day )/TOC , or Day 28 (¬± 2 days ) visit 
Indeterminate  Patient was lost to follow -up or an assess ment was not 
undertaken such that no urine culture was obtained (or culture 
results could not be interpreted for any reason) at the time -point 
of analysis, i.e., Day 5 ( + 1 day) , Day 12 (¬± 1 day )/TOC , or Day 
28 (¬± 2 days ) visit 
7.2.3 Patient -Determined Clinical Response  
A patient will be defined as a clinical success  if the following criteria are met (programmatically, 
based on the data on the eCRF) : 
‚Ä¢ The patient is alive  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 47 of 84 ‚Ä¢ The patient has received no rescue therapy for uUTI  
- If an antibio tic active against the urinary tract pathogen is given for other reasons, then 
the patient will be considered indeterminate  
‚Ä¢ The patient has resolution of the symptoms of uUTI present at trial entry and no new uUTI 
symptoms (based on the Patient Symptom Ass essment Questionnaire)  
- Baseline symptoms associated with another known condition (e.g., overactive bladder) do not need to be resolved 
All other patients will be considered as failures  unless data are unavailable to determine if the 
patient is a success  or a failure . In this case, the patient will be considered as having an 
indeterminate response. Patients with an indeterminate response are included in the denominator 
for determination of the response rate.  
7.2.4 Investigator Assessment of Clinical Response 
Investigators will use the definitions below to document clinical response, irrespective of 
microbiologic findings, at Day 5 (+ 1 day) , Day 1 2 (¬± 1 day)/TOC , Day 28 (¬± 2 days), or 
Premature Discontinuation: 
Clinical response Definition  
Clinical success  All pre -therapy signs and symptoms of the index infection had resolved such 
that no additional antibiotics were required 
Clinical failure  Patients who met any one of the criteria below to be considered as failure:  
Death related to uUTI prior to visit 
Persistence or progression of any  pre-therapy uUTI signs and symptoms or use 
of additional antibiotics for the current infection  
Patient previously met criteria for failure  and received rescue antibiotics   
Indeterminate  Data not available for evaluation of efficacy for any reason, including  but not 
limited to : 
Patient lost to follow -up or assessment not undertaken such that a 
determination of clinical response could not be made at  the visit 
Death prior to study visit, where uUTI was clearly noncontributory  
 
7.2.5 Patient Symptom Assessment Questionnaire (PSAQ)  
Patients will score their UTI symptoms and record them on a Patient Symptom Assessment 
Questionnaire.  PSAQ is administered on Day 1 (prior to first dose) , Day 5 (+ 1 day)/EOT, 
Day 12 (¬± 1 day) /TOC, and Day 28 (¬± 2 days)  visit, or P remature Discontinuation. In the 
event that rescue therapy is prescribed, patient symptoms will be collected as an unscheduled event.  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -[ADDRESS_324431](s) will be reported as described in the following sections.  
For all AEs, the investigator must pursue and obtain adequate information both to determine the 
outcome of the AE and to assess whether it meets the criteria for classification as a serious AE  
(SAE) requiring immediate notification to Iterum Therapeutics ‚Äô designated pharmacovigilance 
provider (Medpace Safety) .  For all AEs,  sufficient information should be obtained by [CONTACT_167328].  The investigator is required to assess causality.  All AEs will be followed -up by [CONTACT_266528] a level acceptable to the investigator, and Iterum concurs with that assessment.  
8.2 
Reporting Period  
Adverse events will be collected from the time that the patient provides informed consent 
through the Day  28 (¬± 2 days) ( Final Visit) .  
For SAEs, the reporti ng period to Iterum Therapeutics ‚Äô designated pharmacovigilance provider 
(Medpace Safety)  begins from the time that the patient provides informed consent, which is 
obtained prior to the patient‚Äôs participation in the study, i.e., prior to undergoing any study-
related procedure and/or receiving investigational product, through the Final Visit.  Any SAE 
occurring any time after the reporting period must be promptly reported if a causal relationship 
to investigational product is suspected.  
All AEs should be recorded on the CRF if they occur from the time the patient provides 
informed consent through Final Visit.  
8.[ADDRESS_324432] or medical device , unless the event is captured in the study endpoint,  as defined below ; 
the event need not necessarily have a causal relationship with the treatment or usage.   
An event would be considered as adequately captured in the study endpoint if it is accurately and 
fully represented by a protocol -defined reason for clinical failure (other than mortality) or 
relapse.  Such an event should not be reported as an adverse event unless it is a serious adverse 
event as defined in this protocol.   
Events represented by [CONTACT_1758] e ndpoints, which would not be considered AEs,  include all of 
the following:  
‚Ä¢ Symptoms of uUTI have not resolved from Baseline to such an extent that new antibiotics 
are needed for the infection under study 
‚Ä¢ Development of new uUTI symptoms not present at Base line 
‚Ä¢ Follow up urine cultures do not reveal eradication of causative uropathogen  
Except for circumstances as defined above, examples of AEs include but are not limited to:   IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 49 of 84 ‚Ä¢ Abnormal test findings (see  Section  8.4) 
‚Ä¢ Clinically significant symptoms and signs  
‚Ä¢ Changes in physical examination findings  
‚Ä¢ Hypersensitivity  to study drugs  
‚Ä¢ Progression/worsening of underlying disease  (not UTI)   
Additionally, they may include the signs or symptoms resulting from:  
‚Ä¢ Drug overdose  
‚Ä¢ Drug withdrawal  
‚Ä¢ Drug abuse  
‚Ä¢ Drug misuse  
‚Ä¢ Drug interactions  
‚Ä¢ Drug dependency 
‚Ä¢ Exposure during Pregnancy  
8.[ADDRESS_324433] finding (e.g., an abnormal liver function test result) should be 
reported as an AE only if the following conditions apply:  
‚Ä¢ Test result is associated with accompanying symptoms and/or signs, constituting a clinical 
syndrome (e.g., abnormal liver function test results, jaundice, and hepatic tenderness 
suggesting a diagnosis of hepatitis), and/or  
‚Ä¢ Test result requires medical/surgical intervention, and/or  
‚Ä¢ Test result leads to a change in study dosing or withdrawal from the study, significant 
additional concomitant drug treatment, or  other therapy.  
Merely repeating an abnormal test, in the absence of any of the above conditions, does not define 
the abnormal objective test finding as an AE.  Any abnormal test result that is determined to be 
an error does not require reporting as an AE.  Additional diagnostic testing and /or 
medical/surgical interventions that occur as a result of an adverse event due to an abnormal lab test finding should be noted in the CRF.  
8.5 
Serious Adverse Events (SAE ) 
An SAE or serious adverse drug reaction is any untoward medical occurrence at any dose that:  
‚Ä¢ Results in death;  
‚Ä¢ Is life -threatening (immediate risk of death);  
‚Ä¢ Requires inpatient hospi[INVESTIGATOR_1081];  
‚Ä¢ Results in persistent or significant disability/incapacity; 
‚Ä¢ Result s in congenital anomaly/birth defect ; IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 50 of 84 ‚Ä¢ Is assessed as being a medically important event based on medical and scientific judgment.  
Such medically important events may not be immediately life -threatening or result in death 
or hospi[INVESTIGATOR_059], but may jeopardize the patient and may require medical  or surgical 
intervention to prevent one of the above outcomes.  Examples of such events include allergic 
bronchospasm requiring intensive treatment in an emergency room or at home, blood 
dyscrasias or convulsions that do not result in inpatient hospi[INVESTIGATOR_1838], or the development of 
drug dependency or drug abuse.  
8.6 Hospi[INVESTIGATOR_266494].  Admission also includes transfer within the hospi[INVESTIGATOR_4591]/intensi ve care unit (e.g., 
from the psychiatric wing to a medical floor, medical floor to a coronary care unit, neurological 
floor to a tuberculosis unit).  
Hospi[INVESTIGATOR_4592]:  
‚Ä¢ Rehabilitation facilities; 
‚Ä¢ Hospi[INVESTIGATOR_4593]; 
‚Ä¢ Respi[INVESTIGATOR_4594] (e.g., caregiver relief);  
‚Ä¢ Skilled nursing facilities; 
‚Ä¢ Nursing homes;  
‚Ä¢ Routine emergency room evaluation ; 
‚Ä¢ Same day surgeries (as outpatient/same day/ambulatory procedures).  
Hospi[INVESTIGATOR_4595] a precipi[INVESTIGATOR_2505], clinical AE is not in itself an SAE.  Examples include:  
‚Ä¢ Admission for treatment of a preexisting condition not associated with the development of a 
new AE or with a worsening of the preexisting condition (e.g., for work- up of persistent pre -
treatment la boratory abnormality);  
‚Ä¢ Social admission (e.g., patient has no place to sleep);  
‚Ä¢ Administrative admission (e.g., for yearly physical exam);  
‚Ä¢ Protocol- specified admission during a study (e.g., for a procedure required by [CONTACT_17143]); 
‚Ä¢ Optional admission  not associated with a precipi[INVESTIGATOR_4596] (e.g., for elective cosmetic 
surgery).  Pre -planned treatments or surgical procedures should be noted in the baseline 
documentation for the entire protocol and/or for the individual patient;  
‚Ä¢ Admission exclusively for the administration of blood products.  
Diagnostic and therapeutic non- invasive and invasive procedures, such as surgery, should not be 
reported as an AE.  However, the medical condition for which the procedure was performed 
should be reported if i t meets the definition of an AE.  For example, an acute appendicitis that 
begins during the AE reporting period should be reported as the AE and the resulting 
appendectomy should be recorded as treatment of the AE.  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 51 of 84 8.7 Severity Assessment  
The investigator will  use the adjectives MILD, MODERATE, or SEVERE to describe the 
maximum intensity of the AE.  For purposes of consistency, these intensity grades are defined as 
follows: 
‚Ä¢ MILD :  Does not interfere with the patient's usual function.  
‚Ä¢ MODERATE :  Interferes to so me extent with the patient's usual function.  
‚Ä¢ SEVERE:  Interferes significantly with the patient's usual function.   
Note the distinction between the severity and the seriousness of an adverse event.  A severe 
event is not necessarily a serious event.  For example, a headache may be severe (interferes 
significantly with patient 's usual function) but would not be classifi ed as serious unless it met 
one of the criteria for serious adverse events, listed above.  
8.8 Causality Assessment  
The investigator‚Äôs assessment of causality must be provided for all AEs (serious and non-serious); the investigator must record the causal relationship in the CRF, as appropriate, and 
report such an assessment in accordance with the serious adverse reporting requirements if 
applicable.  An investigator‚Äôs causality assessment is the determination of whether there exists a 
reasonable possibility that  the investigational product caused or contributed to an AE.  If the 
investigator does not know whether or not investigational product caused the event, then the event will be handled as ‚Äúrelated to investigational product‚Äù for reporting purposes, as defined by 
[CONTACT_1034] (see Section  8.12 on Reporting Requirements).  If the investigator's causality 
assessment is "unknown but not related to investigational product", this should be clearly documented on study records.  Specifically, the investigator will choose whether the AE is unrelated, unlikely related, possibly related or probably related to the investigational product.  
In addition, if the investigator determines an SAE is associated with study procedures, the 
investigator must record this causal relationship in the source documents and CRF, as 
appropriate, and r eport such an assessment in accordance with the SAE reporting requirements, 
if applicable.  
The Investigator will assess causal ity of the event in relation to study drugs  based on the 
following defined criteria:  
‚Ä¢ UNRELATED: No relationship between the event  and medicinal product  
‚Ä¢ UNLIKELY: Event or laboratory test abnormality, with a time to drug intake that makes a 
relationship improbable (but not impossible); Disease or other drugs provide plausible 
explanations 
‚Ä¢ POSSIBLY : Event or laboratory test abnormality, with reasonable time relationship to drug 
intake; Could also be explained by [CONTACT_19699]; Information on drug withdrawal may be lacking or unclear  
‚Ä¢ PROBABLY : Event or laboratory test abnormality, with reasonable time relationship to drug 
intak e; Unlikely to be attributed to disease or other drugs; Response to withdrawal clinically 
reasonable; Rechallenge not required  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 52 of 84 8.9 Exposure during Pregnancy  
For investigational products and for marketed products, an exposure during pregnancy (also 
referred to as exposure in-utero [EIU]) occurs if:  
1. A female becomes, or is found to be, pregnant either while receiving or having been directly 
exposed to (e.g., environmental exposure) the investigational product, or the female becomes, 
or is found to be, pregnant after discontinuing and/or being directly exposed to the 
investigational product (maternal exposure);  
2. A male has been exposed, either due to treatment or environmental exposure, to the 
investigational product prior to or around the time of his partner‚Äôs conception and/or is exposed during his partner‚Äôs pregnancy (paternal exposure).  
If any study patient or study patient‚Äôs partner becomes  or is found to be pregnant during the 
study patient‚Äôs treatment with the investigational product,  no further study drugs  should be 
given, and the investigator must  submit this information to Iterum Therapeutics ‚Äô designated 
pharmacovigilance provider (Medpace Safety)  on a Pregnancy Form.   
This reporting must be done irrespective of whether an AE has occurred and within 24 hour s of 
awareness of the pregnancy.  The in formation submitted should include the anticipated date of 
delivery (see below for information related to induced termination of pregnancy).  
Follow- up is conducted to obtain pregnancy outcome information on all Pregnancy  reports with 
an unknown outcome.  The investigator will follow the pregnancy until reporting of birth or until 
pregnancy termination (i.e., induced abortion) and then notify Iterum  of the outcome.  The 
investigator will provide this information as a follow up to the initial Pregnancy  Form.  The 
reason(s) for an induced abortion should be specified.  A  Pregnancy report is not created when 
an ectopic pregnancy report is received since this pregnancy is not usually viable.  Rather, an SAE case is created with the event of ectopic pregnancy.  
If the outcome of the pregnancy meets the criteria for immediate classification as an SAE 
(i.e., spontaneous abortion, stillbirth, neonatal death, or congenital anomaly [including that in an 
aborted fetus, stillbirth or neonatal death]), the investigator should follow the procedures for reporting SAEs.  
In the case of a live birth, the ‚Äúnormality‚Äù of the newborn can be assessed at the time of birth 
(i.e., no minimum follow -up period of a presumably normal infant is required before a 
Pregnancy  Form can be completed).  The ‚Äúnormality‚Äù of an aborted fetus can be assessed by 
[CONTACT_4692], unless pre -abortion test findings are suggestive of a congenital anomaly.  
Additional information about pregnancy outcomes that are classified as SAEs follows:  
‚Ä¢ ‚ÄúSpontane ous abortion‚Äù includes miscarriage and missed abortion.  
‚Ä¢ All neonatal deaths that occur within [ADDRESS_324434] to causality, as SAEs.  In addition, any infant death after 1 month that the investigator  assesses 
as possibly related to the exposure during pregnancy to the investigational medication should be reported.  
Additional information regarding the exposure during pregnancy may be requested by [CONTACT_093].  Further follow -up of birth outcomes w ill be handled on a case-by- case basis IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 53 of 84 (e.g.,  follow- up on preterm infants to identify developmental delays).  In the case of paternal 
exposure, the investigator must obtain permission from the patient‚Äôs partner in order to conduct 
any follow -up or collect  any information.  
8.10 Discontinuation from Study Drug Due to AEs (See also Patient Withdrawal, 
Section 6.5) 
Discontinuation from study drug due to an AE should be distinguished from discontinuation due 
to insufficient response, according to the definition of AE noted earlier, and recorded on the 
appropriate AE CRF page.   
When a patient discontinues study drug due to an SAE, the SAE must be reported in accordance with the reporting requirements defined below.  
8.[ADDRESS_324435] possibly related to s tudy drug,  
expedited reporting will follow local and international regulations, as appropriate.  
8.12.1  SAE Reporting Requirements  
If an SAE or exposure during pregnancy occurs, Iterum Therapeutics ‚Äô designated 
pharmacovigilance provider  (Medpace Safety ) is to be notified within 24  hours of awareness of 
the event by [CONTACT_266529]. When the form in 
EDC is completed, Medpace Safety personnel will be notified electronically by [CONTACT_266530]. If the event meets serious criteria and it is not possible to access the 
EDC system, send an email to Medpace Safety at  medpace- [EMAIL_5161]  or 
call the Medpace SAE reporting line (phone number listed below), and fax/email the completed 
paper SAE form to Medpace within [ADDRESS_324436] be made 
immediately, irrespective of the extent of available event  information.  This timeframe also 
applies to additional new information (follow -up) on previously forwarded SAE repor ts as well 
as to the initial and follow -up reporting of Pregnancy cases.   
In the rare instance that the investigator does not become aware of the occurrence of an SAE 
immediately (e.g., if an outpatient study patient initially seeks treatment elsewhere), the 
investigator is to report the event within 24 hour s after learning of it and document the time of 
his/her first awareness of the AE.  
For all SAEs and  pregnancies , the investigator is obligated to pursue and provide information to 
Iterum in accordance w ith the timeframes for reporting specified above.  In addition, an IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 54 of 84 investigator may be requested by [CONTACT_104536]‚Äô designated pharmacovigilance provider 
(Medpace Safety)  to obtain specific additional follow -up information in an expedited fashion.  
This information may be more detailed than that captured on the SAE form .  In general, this 
information may include hospi[INVESTIGATOR_44458], laboratory test and X -ray results .  
Information on other possible causes of the event, such as concomitant medications and illnesses 
must be provided.  In the case of a patient death, a summary of available autopsy findings must 
be submitted as soon as possible to Iterum Therapeutics‚Äô designated pharmacovigilance provider 
(Medpace Safety) .  The information should be reported on an SAE/ Pregnancy form and sent  to 
Iterum Therapeutics‚Äô designated pharmacovigilance provider  (Medpace Safety ). 
 
8.12.2  Non-SAE Reporting Requirements  
All AEs /SAEs  will be reported on the AE page(s) of the CRF.    Adverse events  should be 
reported using concise medical terminology on the CRFs .  
8.12.3  Sponsor Reporting Requirements to Regulatory Authorities  
Adverse event reporting, including reporting of Suspected, Unexpected Serious Adverse Reactions  (S[LOCATION_003]Rs) , will be carried out in accordance with applicable local regulations.  Death 
and life -threatening S[LOCATION_003]Rs are subject to expedited reporting within a 7- calendar  day (life -
threatening and fatal) or 15 calendar day (all other S[LOCATION_003]Rs) timeframe.  
9 DATA ANALYSIS/STATISTICAL METHODS  
9.1 Sample Size Determination  
The study is designed to determine whether oral sulopenem is NI to oral amoxicillin/clavulanate  
for the outcome measure of overall success (combined clinical and microbiol ogic success) at 
Day 12 (¬± 1 day) /TOC  in both the micro -MITT and micro -MITTS populations and whether oral 
sulopenem is superior to oral amoxicillin/clavulanate  for overall success at Day 12 (¬± 1 
day)/TOC  in the micro -MITTR population.  The primary outcome m easure of overall success 
(combined clinical  and microbiologic success) is defined as resolution of the symptoms of uUTI 
present at trial entry (and no new symptoms), and the demonstration that the bacterial pathogen 
found at trial entry is reduced to <103 CFU/mL on urine culture (microbiological success 
[eradication] ). 
The proposed sample size  in the micro -MITTS population is 505 patients per arm  (total of 1010 
patients)  based on the method of Farrington and Manning. This assumes a non- inferiority margin 
of 10.0 %, a power of 90%, a one -sided alpha level of 0.025 , 60% overall  success  rate with 
amoxicillin/clavulanate and 6 0% overall rate with sulopenem etzadroxil/probeneci d.  Assuming 
that 21% of the patients will have non-susceptible pathogens and assuming 85% power to show 
superiority in the micro -MITTR population (micro -MITT=1278 patients ), 67% of the 
randomized patients will meet criteria for inclusion into the micro -MITT population 
(MITT= 1907 patients) and allowing for a dropout rate of 3%, the sample size for the ITT 
population is 1966. With [ADDRESS_324437] 85% power to show superiority at the one- sided 2.5% alpha level  given a 51% and 
33% overall success rate in the oral sulopenem and amoxicillin/clavulanate  groups, respectively. 
With [ADDRESS_324438] 95% power to show non-IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 55 of 84 inferiority (non- inferiority margin of 10.0%) at the one -sided alpha level of 0.025 with the 
treatment success rates of the oral sulopenem and amoxicillin/clavulanate  groups assumed to be 
58% in this population.   
One blinded interim analys is for sa mple size re- estimation is planned (See Section 9.7).  
9.2 Definition of Analysis Populations  
1. Intent -to-Treat ( ITT): all randomized patients  regardless of whether or not the patient 
received study drug  
2. Modified ITT (MITT) : randomized patients who received at least a single  dose of study 
medication . Patients will be analyzed according to the treatment to which they were 
randomized. 
3. Safety : randomized patients who received at least a single  dose of study medication . 
Patients will be analyzed accordin g to the treatment that they received.  
4. Micro -MITT : All MITT patients with a positive study entry urine culture defined as 
‚â•105 CFU/mL of a uropathogen (Enterobacterales  or Staphylococcus saprophyticus only) 
and no more than 2 species of microorganisms identified in the study entry urine culture, 
regardless of colony count.  
5. Micro- MITTS : All micro -MITT patients with a baseline uropathogen susceptible 
(defined as MIC < 8/4 mg/L) to the comparator drug, amoxicillin/clavulanate , and no 
baseline pathogen non- susceptible  to amoxicillin/clavulanate . 
6. Micro -MITTR : All micro -MITT patients with a baseline uropathogen non-susceptible 
[intermediate (MIC 16/8 mg/L) or resistant (MIC ‚â• 32/16 mg/L)] to the comparator drug, 
amoxicillin/clavulanate . 
7. Clinically Evaluable: Clinically E valuable (CE) at the Day 5 (+1 day) , Day 12 (¬±1 
day)/TOC , and Day 28  (¬±2 days)  visits population :  
All patients who were included in the MITT population and:  
a) Received a minimum number of days of study drug (to be defined in the SAP)  
b) Had no important protocol deviations that would affect the assessment of efficacy (to 
be defined in the SAP)  
c) Had a clinical outcome assessment at the relevant  visit and the assessment was within 
the protocol allowed visit window.   
d) Had not received  antibacterial drug therapy potentially effective as treatment of uUTI 
within 7 days  prior to study entry  
e) Did not receive any antibiotic therapy with potential activity against any of the baseline uropathogens collected at Baseline between the time of the baseline culture 
and the Day 5 (+1 day)  or Day 12 (¬±1 day) /TOC  culture, respectively.  This excludes 
the protocol defined study therapy and patients who were considered clinical failures 
and required additional rescue antibiotic therapy.  Patients with a coinfection with a 
gram -positive uropathogen resistant to study drugs are allowed to receive agents with 
narrow spectrum g ram-positive coverage ( i.e., such as oral linezolid) . 
8. Microbiologically evaluable (ME):  all patients in cluded in both the micro -MITT and 
CE populations at the  Day 5 (+1 day)  visit (ME -Day 5 ), Day 12 (¬±1 day) /TOC  visit (ME -
Day 12) and at the Day 28 (¬±2 days)  visit (ME -Day28) and have an appropriately IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 56 of 84 collected urine culture specimen and interpretable urine culture result a t the Day 5 (+1 
day), Day 12 (¬±1 day) /TOC  and Day 28 (¬±2 days)  visits , respectively.  
Amoxicillin/clavulanate breakpoints as per CLSI ( M100 Performance Standards for 
Antimicrobial Susceptibility Testing, 32nd edition ). 
9.[ADDRESS_324439] deviations, medians, minimums, and maximums for continuous 
variables will be provided. All comparisons will be for the oral sulopenem treatment group and 
the amoxicillin/clavulanate  treatment group. Exploratory analyses may also be performed.  
Listings of individual patient‚Äôs data will be produced.  
9.4 Patient Characteristics  
Enrollment, protocol deviations, discontinuations from the study drug and w ithdrawal from the 
study will be summarized by [CONTACT_1570].  Demographics (age, race, sex), medical history , 
baseline assessment of the symptoms of uUTI , microbiological assessment of the urine , and 
study drug administration will also be summarized.   
9.5 Efficacy Analysis  
For all efficacy analyses, patient data will be analyzed in the treatment group to which the patient 
was randomized.   
9.5.1 Analysis of Primary Outcome Measure 
The primary efficacy outcome is overall success  (combined clinical and microbiologi c success ) 
at Day 12 ( ¬± 1 day) /TOC  in the micro -MITT, micro -MITTS and micro- MITTR populations .  
Patients will be programmatically categorized as a success , failure , or indeterminate based on 
data in the eCRF and from the microbiology lab.  Patients with missing data or who are lost to 
follow- up are defined as indet erminate for the primary analyses and are included in the 
denominator for the calculation of the success  rate. The number and percentage of patients with 
success , failure  and indeterminate  response will be determined in each treatment group  in the 
micro -MITT, micro -MITTS and micro- MITTR populations .  
The primary comparison of the study is in the micro- MITT population ( the combined population 
of patients with a positive bas eline culture and without regard to amoxicillin/clavulanate 
susceptibility). These outcomes are most relevant to the practicing clinician who must choose empi[INVESTIGATOR_266486]. From a regulatory 
perspective, thes e results will help put into context the outcomes in the culture and susceptibility- 
driven subpopulations.  
The primary comparisons for regulatory approval are in two mutually exclusive sub -populations 
of the micro -MITT population defined by a baseline characteristic , the micro -MITTS and micro -
MITTR populations.  
To control for inflation of the  overall type I error rate, the hierarchical testing procedure of 
Westfall and Krishen (Westfall 2001) will be used to test the hypotheses of the primary efficacy IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 57 of 84 outcome in these populations in the sequential order described below. Testing will proceed to the 
next comparison, only in the case where the null hypothesis in the previous comparison was 
rejected. When testing in a sequential manner with pre- planned testing,  no adjustment to the 
alpha level is required : 
(1) NI in the micro -MITT population .  For this population, a NI test of the overall success rate 
will be conducted.  The null and alternative hypotheses are the following:  
‚àÜ ‚àí ‚â§ ‚àí2 1 0 : p p H  and ‚àÜ ‚àí > ‚àí2 1 : p p HA , 
where p 1 is the primary efficacy outcome rate in the oral sulopenem group, p 2 is the primary 
efficacy outcome rate in the amoxicillin/clavulanate  group, and Œî is the non- inferiority margin of 
10.0%.  
The NI hypothesis test is a 1- sided hypothesis test performed at the 2.5% level of significance.  
This is based on the lower limit of the 2- sided 95% CI for the observed difference in the overall 
success rate ( oral sulopenem group minus amoxicillin/clavulanate  group).  The primary analysis  
is based on the CI computed using the method proposed without stratification by [CONTACT_240865], which corresponds to the p- value approach of the Farrington- Manning test.  If the 
lower limit of the 95% CI for difference in success rates in the micr o-MITT population is greater 
than -10.0%, the null hypothesis will be rejected and the NI of oral sulopenem to 
amoxicillin/clavulanate  will be concluded.  
 (2) NI the micro -MITTS population OR superiority in the micro- MITTR population as 
described below: 
Micro-MITTS population: the subset of the micro- MITT population in which the baseline 
pathogen is determined to be susceptible to the comparator study drug, amoxicillin/clavulanate. For this population, a NI test of the overall success rate will be conducted. The null and 
alternative hypotheses are as follows:  
‚àÜ ‚àí ‚â§ ‚àí2 1 0 : p p H  and ‚àÜ ‚àí > ‚àí2 1 : p p HA  
A 2-sided 95% CI for the o bserved treatment difference in success rates will be determined. If 
the lower bound of the 95% CI is greater than - 10.0%, the null hypothesis will be rejected and 
the NI of oral sulopenem to amoxicillin/clavulanate in the micro -MITTS population will be 
concluded. 
Micro-MITTR population: the subset of the micro- MITT population in which the baseline 
pathogen is determined to be non-susceptible to the comparator study drug, 
amoxicillin/clavulanate . For this population, a superiority test will be conducted.  The null and 
alternative hypotheses are as follows:  
2 1 0 : p p H= and 2 1 : p p HA‚â† 
A 2-sided 95% CI for the o bserved treatment difference in success rates will be determined using 
the method without stratification of Miettinen and Nurminen.  If the lower bound of the 95% CI is greater than 0%, the null hypothesis will be rejected and super iority of oral sulopenem to 
amoxicillin/clavulanate  will be concluded in the micro -MITTR population. IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 58 of 84 Each of the 2 null hypotheses in this step will be tested at the 2.5% level and if either hypothesis 
is rejected, then testing will proceed to the next ste p. 
(3) Superiority test of overall success, ùêªùêª 0:ùëùùëù1=ùëùùëù2 and ùêªùêªùê¥ùê¥:ùëùùëù1‚â† ùëùùëù2, in the micro -MITT 
population. If the lower bound of the 95% CI (calculated for the hypothesis test in (1) is greater 
than 0%, the null hypothesis will be rejected and the superiority of oral sulopenem to 
amoxicillin/clavulanate in the micro -MITT population will be concluded.  
 
9.5.[ADDRESS_324440] missing data for 
the primary outcome ( i.e., an indeterminate response) as successes .  A 2 -sided 95% unstratified 
CI will be computed for the difference in the success rates between the treatment groups.  A 
sensitivity analysis applying multiple imputation methods for missing data will be conducted.  A 
sensitivity analysis based on results of  whole genome sequencing to confirm susceptibility 
testing results will also be conducted.  An analysis of the overall response at Day 12 (¬±1 
day)/TOC may be performed after adjusting for covariates . 
Additional sub- group analyses, such as the effect of food  or based on baseline variables 
including geographic region if applicable, may be conducted as exploratory analyses.   
9.5.3 Analysis of Secondary Efficacy Outcome Measure 
The number and percentage of patients in each treatment group with a clinical response of 
success, failure and indeterminate at Day 12 (¬±1 day) /TOC  will be presented for the MITT, 
micro -MITT, micro -MITTS, and micro -MITTR populations. The number and percent age of 
patients in each treatment group with a clinical response of success and failure at Day 12 (¬±1 
day)/ TOC  will be presented for the CE and ME populations.  Two-sided 95% unstratified  CIs 
will be constructed for the obs erved difference in the clinical  success  rates between the treatment 
groups for descriptive purposes ; no conclusion of NI will be made.  
The number and percentage of patients in each treatment group with asymptomatic bacteriuria at Day 12 (¬±1 day) /TOC  will be presented for the micro -MITT,  micro -MITTS, micro -MITTR and 
ME populations . The difference in rate of asymptomatic bacteriuria (oral sulopenem group 
minus the amoxicillin/clavulanate  group) will be determined and 2-sided 95% unstratified CIs 
will be constructed for the obs erved difference between the treatment groups for descriptive 
purposes; no conclusion of NI will be made.  
 The number and percentage of patients in each treatment group with a microbiologic response of 
success, failure and indeterminate at Day 12 (¬±1 day) /TOC  will be p resented for the micro -
MITT, micro -MITTS, and micro -MITTR populations. The number and percentage of patients in 
each treatment group with a microbiologic response of success and failure at Day 12 (¬±1 
day)/ TOC  will be presented for the  ME populations.  Two-sided 95% unstratified CIs will be 
constructed for the obs erved difference in the microbiologic success  rates between the treatment 
groups for descriptive purposes ; no conclusion of NI will be made.  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 59 of 84 9.5.4 Analyse s of Additional Efficacy Outcome Measures 
The number and percentage of patients in each treatment group with a clinical response of 
success, failure and indeterminate at Day 5 (+1 day) , and Day 28 (¬±2 days)  will be presented for 
the MITT, micro -MITT, micro -MITTS, and mic ro-MITTR populations. The number and 
percentage of patients in each treatment group with a clinical response of success and failure at 
Day 5 (+1 day), and Day 28 (¬±2 days)  will be presented for the CE and ME populations.  Two-
sided 95% unstratified  CIs will be constructed for the obs erved difference in the clinical  success  
rates between the treatment groups for descriptive purposes ; no conclusion of NI will be made.  
The number and percentage of patients in each treatment group with asymptomatic bacteriuria at Day 5 (+1 day), and Day 28 (¬±2 days)  will be presented for the micro -MITT, micro -MITTS, 
micro -MITTR  and ME populations . The difference in rate of asymptomatic bacteriuria (oral 
sulopenem group minus the amoxicillin/clavulanate  group) will be determined and 2-sided 95% 
unstratified  CIs will be constructed for the obs erved difference between the treatment groups for 
descriptive purposes ; no conclusion of NI will be made.  
 The number and percentage of patients in each treatment group with a microbiologic response of 
success, failure and indeterminate at Day 5 (+1 day) , and Day 28 (¬±2 days)  will be presented for 
the micro -MITT, micro -MITTS, and micro -MITTR populations. The number and percentage of 
patients in each treatment group with a microbiologic response of success and failure at Day 5 
(+1 day), and Day 28 (¬±2 days)  will be presented for the ME population.  Two- sided 95% 
unstratified  CIs will be constructed for the obs erved difference in the microbiologic success  rates 
between the treatment groups for descriptive purposes ; no conclusion of NI will be made.  
The number and percentage of patients in each treatment group with an overall response of success, failure and indeterminate at Day 5 (+1 day) , and Day 28 (¬±2 days)  will be presented for 
the micro -MITT, micro -MITTS and micro -MITTR populations. The number and percentage of 
patients in ea ch treatment group with an overall response of success and failure at Day 5 (+1 
day), Day 12 (¬±1 day) /TOC  and Day 28 (¬±2 days)  will be presented for the ME population. Two-
sided 95% unstratified  CIs will be constructed for the obs erved difference in the overall success  
rates between the treatment groups for descriptive purposes ; no conclusion of NI will be made.  
Investigator determined clinical response (clinical success , failure and indeterminate) at the Day 
5 (+1 day) , Day 12 (¬±1 day) /TOC , and Day 28 (¬±2 days) visits will be presented by [CONTACT_266531], micro -MITT, micro -MITTS, micro -MITTR, and the respective CE and ME  
populations.  Two- sided 95% unstratified CIs will be constructed for the observed difference in 
the clinical cure rates between the treatment groups for descriptive purposes.  
A shift table of the severity of each uUTI symptom based on the Patient Symptom Assessment Questionnaire from baseline to Day 5 (+1 day) , Day 12 (¬±1 day) /TOC , Day 28 (¬±2 days)  and 
relevant unscheduled visits will be provided by [CONTACT_259498]- MITTS and micro -
MITTR populations.  
Overall success , clinical success,  and microbiologic success at the Day 5 (+1 day) , Day 12 (¬±1 
day)/ TOC  and Day 28 (¬±2 days) visits by [CONTACT_266532] (key pathogens) will be summarized 
by [CONTACT_259501] -MITT, micro -MITTS, micro -MITTR and ME populations.  
The number and percentage of patient s in each treatment group with a microbiologic response of 
complete eradication (define d as no growth of baseline pathogen on a follow -up urine culture at IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 60 of 84 Day 12 (¬±1 day) /TOC ) will also be presented for the m icro-MITT , micro -MITTS, micro -MITTR 
and ME populations.  
The number and percentage of patient s in each treatment group with a microbiologic response of 
complete eradication ( defined as no growth of baseline pathogen on a follow -up urine culture at 
Day 12 (¬±1 day) /TOC ) and monomicrobial infection will also be presented for the m icro-MITT , 
micro -MITTS, micro -MITTR and ME populations.  
An asse ssment of the impact of antibiotic therapy  on the in vitro  susceptibility of study 
uropathogens (Enterobacterales and S.  saprophyticus ) identified at baseline  will be  performed at 
the D12 (¬±1 day)/TOC  and Day 28 (¬±2 days) visits in order to determine if study drug select ed 
for organisms with higher MIC‚Äôs . 
An assessment of overall response by [CONTACT_266533](es) will be presented 
in each treatment group for the m icro-MITT , micro -MITTS, micro -MITTR and ME populations.  
Sub- group analyses, such as the effect of food, may be conducted for selected secondary safety 
and efficacy outcomes as exploratory analyses.  
9.6 Safety Analyses  
Safety will be assessed through summaries of AEs, clinical laboratory tests,  and vital signs.  All 
safety analyses will be based on the Safety population.  Patients who receive the wrong regimen 
of study drug for their entire course of treatment will be analyzed in the group based on the 
regimen received.  
Adverse events will be coded using the Medical Dictionary of Regulatory Activities (MedDRA). 
Summary tables of treatment- emergent AEs (TEAEs) will be provided.  A TEAE is any AE that 
newly appeared or  worsened in severity following initiation of study drug.  The  incidence of 
TEAEs will be tabulated by [CONTACT_9313] (SOC) and preferred term (PT) for each 
treatment group , by [CONTACT_2946], PT and severity and by [CONTACT_2946], PT and relationship to treatment.  Tables 
of TEAEs leading to study drug discontinuation, withdrawal from the study or an SAE will be 
provided.  AEs occurring prior to the first dose of study drug (AEs are recorded from the time of 
informed consent) will be provided in a listing.  
Descriptive statistics summ arizing central laboratory data (hematology and chemistry) will be 
presented for the Baseline and Day 12 (¬± 1 day) /TOC  study visits.  The change from baseline to 
each post -baseline visit and to the overall worst post -baseline value will also be s ummarized by 
[CONTACT_1570].  Laboratory values will be classified as potential ly clinical ly significant and the 
number and percentage of patients with a PCS lab value will be summarized by [CONTACT_10663].   Descriptive statistics of the vital s igns will be presented by [CONTACT_266534], Day 5 (+1 day), and Day 12 (¬± 1 day) /TOC  study visit s, as well as the change from 
baseline at the Day 5 (+1 day)  and Day 12 (¬± 1 day) /TOC  study visit s.   
9.7 Interim Analysis   
To ensure that the point estimate of overall success (combined clinical and microbiologic 
success ) used in the estimation of sample size , and the estimated eligibility rate, susceptibility 
rate, and rate of post -treatment asymptomatic bacteriuria is valid f or this study, an interim 
analys is for sample size re- estimation will be performed when clinical and microbiologic IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 61 of 84 response data at Day 12 (¬± 1 day) /TOC  are available for approximately 50 % of the patients 
(approximately 983 patients ).  The FDA Guidance ‚ÄúNon -inferiority Clinical Trials‚Äù [ FDA 
Guidance 2016] notes that such a sample size re- estimation if based on the blinded overall 
response rates is not only acceptable but is advisable.  The interim analysis will involve a 
sample size re- estimatio n to either confirm the initial sample size estimate is adequate or 
increase the sample size (number of randomized patients) to ensure the study has adequate power . The sample size of the study will be computed to ensure that there is sufficient power 
for determining whether oral sulopenem is NI to oral amoxicillin/clavulanate  for the primary 
outcome measure in the micro -MITTS population. This will ensure that the study is sufficiently 
powered to test the primary endpoint in the micro- MITT and micro -MITTR p opulations as 
well. The sample size will not be decreased.   In addition, the sample size may be increased 
based on a lower -than-expected  evaluability rate  (i.e., percentage of the ITT population in the 
micro -MITT population) , higher- than-expected  rate of asymptomatic bacteriuria  or lower than 
expected percentage of patient s with a susceptible pathogen. The sample size re- estimation will 
be based on the blinded overall (not by [CONTACT_1570]) pooled data . 
The blinded interim analys is will proceed as follow s: 
1. Determine the percentage of patients with a baseline pathogen (micro -MITT population)  
2. Determine the percentage of patients with a susceptible (to comparator study drug , 
amoxicillin/clavulanate ) pathogen (micro- MITTS population) and a non-susceptible (to 
amoxicillin/clavulanate ) pathogen (micro -MITTR population)  
3. Determine the overall success rate and overall rate of asymptomatic bacteriuria 
aggregated across treatment groups in the micro -MITTS population  
4. Determine if there is sufficient power (80 -90%) in the micro- MITTS to show NI with 
the planned sample size based on the observed aggregated (across treatment groups) 
overall success rate and overall rate of asymptomatic bacteriuria  
a. If NO, then increase the sample size in the micro -MITTS population to have 
sufficient power, up to a maximum number of 2500 patients.  
5.  If the aggregated overall success rate in the micro -MITTS population is higher than 
70%, or if the aggregated rate of asymptomatic bacteriuria  is significantly lower than 
anticipated, then a futility analysis may be conducted by [CONTACT_266535]. Further details of how the DMC will decide to do the futility analysis, 
how the sponsor will be involved and how the analysis will be conducted will be 
provided in the SAP and the DMC charter . 
9.8 Handling of Missing Data  
Details of the handling of missing data will be provided in the SAP.  For the primary and 
secondary efficacy analyses, if any data field needed to determine overall response (primary) 
and microbiological response (secondary) is missing at the Day 12 (¬±1 day) /TOC  (primary) and 
Day 28 (¬±2 days)  (secondary) visit, the patient will be considered an indeterminate response. 
By [CONTACT_108], patients with an indeterminate r esponse are included in the denominator in the 
micro-MITT population and thus, are analyzed in the same manner as failures in the primary 
and secondary analyses. Additional sensitivity analyses for handling missing data will be 
detailed in the SAP. Imputation may be performed to understand the impact of any imbalance IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -[ADDRESS_324441] (IRB)/independent 
ethic s committee (IEC), and/or to quality assurance audits performed by [CONTACT_104581] , or companies 
working with or on behalf of Iterum , and/or to inspection by [CONTACT_4708].  
It is important that the investigator(s) and their relevant personnel are available during the 
monitoring visits and possible audits, or inspections and that sufficient time is devoted to the 
process.  
[ADDRESS_324442] KEEPI[INVESTIGATOR_1645]  
11.1 Case Report Forms / Electronic Data Record  
As used in this protocol, the term CRF should be understood to refer to either a paper form or an 
electronic data record or both, depending on the data collection method used in this study.  
A CRF is required and should be completed for  each included patient.  The completed original 
CRFs are the sole property of Iterum  and should not be made available in any form to third 
parties, except for authorized representatives of Iterum  or appropriate regulatory authorities, 
without written permission from Iterum . 
The investigator has ultimate responsibility for the accuracy, authenticity, and timely collection 
and reporting of all clinical, safety, laboratory data entered on the CRFs and any other data 
collection forms.  The CRFs must be signed by [CONTACT_266536].  Any corrections to entries made in the 
CRFs and source documents must be dated, initialed and explained (if necessary) and should not 
obscure the original entry.  
In most cases, the source documents are the hospi[INVESTIGATOR_307]'s or the physician's patient chart.  In these cases, data collected on the CRFs must match the data in those charts.  
11.[ADDRESS_324443] Retention  
To enable evaluations and/or audits from regulatory authorities or Iterum , the investigator agrees 
to keep records, including the identity of all participating patients (sufficient information to link 
records, e.g., CRFs and hospi[INVESTIGATOR_1097]), all original signed informed consent forms, copi[INVESTIGATOR_104526], SAE forms, source documents, and detailed records of treatment disposition, and 
adequate documentation of relevant correspondence (e.g., letters, meeting minutes, telephone 
call reports).  The records should be retained by [CONTACT_95348] , local 
regulations, or as specified in the Clinical Study Agreement, whichever is longer.  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 63 of 84 If the investigator becomes unable for any reason to continue to retain study records for the 
required period (e.g., retirement, relocation), Iterum  should be prospectively notified.  The study 
records must be transferred to a designee acceptable to Iterum , such as another investigator, 
another institution, or to Iterum .  The investigator must obtain Iterum 's written permission before 
disposing of any records, even if  retention requirements have been met.  
[ADDRESS_324444] (IRB)/Independent Ethics Committee (IEC) 
It is the responsibility of the investigator to have prospective approval of the study protocol, 
protocol amendments, informed consent forms, and other relevant documents, e.g.,  recruitment 
advertisements, if applicable, from the IRB/IEC.  All correspondence with the IRB/IEC should 
be retained in the Investigator File.  Copi[INVESTIGATOR_1099]/IEC approvals should be forwarded to Iterum . 
The only circumstance in which an amendment may be initiated prior to IRB/IEC approval is 
where the change is necessary to eliminate apparent immediate hazards to the patients.  In that 
event, the investigator must notify the IRB/IEC and Iterum  in writing immediately after  the 
implementation.  
12.[ADDRESS_324445] of the Study 
The study will be conducted in accordance with the Declaration of Helsinki on Ethical Principles 
for Medical Research Involving Human Patients, adopted by [CONTACT_266537] (2013).  
In addition, the study will be conducted in accordance with the protocol, the International 
Conference on Harmonisation (ICH) guideline on Good Clinical Practice (GCP), and applicable 
local regulatory requirements and laws.  
12.[ADDRESS_324446] be prospectively approved by [CONTACT_28150]/IEC and Iterum  before use.  
The investigator must ensure that each study patient is fully informed about the nature and 
objectives of the study and possible risks associated with participation.  The investigator, or a 
person designated by [CONTACT_093], will obtain written informed consent from each patient 
before any study- specific activity is performed.  The i nvestigator will retain the original of each 
patient's signed consent form.  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 64 of 84 12.4 Reporting of Safety Issues and Serious Breaches of the Protocol or 
ICH GCP 
In the event of any prohibition or restriction imposed (i.e., clinical hold) by [CONTACT_259503] w orld, or if the investigator becomes  aware of any new 
information which might influence the evaluation of the benefits and risks of the investigational 
product, Iterum  should be informed immediately.   
In addition, the investigator will inform Iterum  immediately of any urgent safety measures taken 
by [CONTACT_4713], and of any serious 
breaches of this protocol  or of ICH GCP that the investigator becomes aware of.  
[ADDRESS_324447] patient‚Äôs Final Visit. 
14 SPONSOR STUDY TERMINATION CRITERIA 
Premature termination of this study may occur because of a regulatory authority decision, change 
in opi[INVESTIGATOR_1100]/IEC, drug safety problems, or at the discretion of Iterum .  In addition, 
Iterum  retains the righ t to discontinue development of sulopenem  at any time.  
If a study is prematurely terminated, Iterum  will promptly notify the investigator and the 
investigator must also inform the IRB/IEC.  After notification, the investigator must contact [CONTACT_266538][INVESTIGATOR_4601] (if appli cable) within [ADDRESS_324448] (eudract.ema.europa.eu)  as 
applicable. 
15.[ADDRESS_324449] inadve rtent disclosure of Confidential Information or 
unprotected Inventions, the Investigator will provide Iterum  an opportunity to review any 
proposed publication or other type of disclosure before it is submitted or otherwise disclosed.  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 65 of 84 The Investigator will provide manuscripts, abstracts, or the full text of any other intended 
disclosure (poster presentation, invited speaker or guest lecturer presentation, etc.) to Iterum  at 
least [ADDRESS_324450], remove any previously undisclosed Confidential Information (other than the study results themselves) before disclosure.  
If the study is part of a multi -center  study, the Investigator agrees that the first publication is to 
be a joint publication covering all centers.  However, if a joint m anuscript has not been submitted 
for publication within [ADDRESS_324451] to the other requirements of this section.  
For all publications relating to the study, the Institution will comply with recognized ethical 
standards concerning publications and authorship, including Section  II - ‚ÄúEthical Considerations 
in the Conduct and Reporting of Research‚Äù of the Uniform Requirements for Manuscript s 
Submitted to Biomedical Journals, http://www.icmje.org/index.html#authorship, established by 
[CONTACT_104586].  
Publication of study results is also provided for in the Clinical Study Agreement between Iterum  
and the Institution.  In this section entitled Publications by [CONTACT_4718], the defined terms shall 
have the meanings given to them in the Clinical Study Agreement.  
 IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -[ADDRESS_324452] 
Banerjee R and Johnson JR. A New Clone Sweeps Clean: the Enigmatic Emergence of 
Escherichia coli Sequence Type 131. AAC 2014:58:4997-5004. 
Brannon JR, Dunigan TL, Beebout CJ, et al. Invasion of vaginal epi[INVESTIGATOR_266495] . Nature Communications 2020;11:2803.  
Brumfitt W, and Hamilton- Miller JMT. Amoxicillin plus clavulanic acid in the treatment of 
recurrent urinary tract infections. Antimicrob Agents Chemother 1984;25(2):276-278. 
CLSI M100- ED32:2022 Performance Standards for Antimicrobial Susceptibility Testing, 32nd 
Edition. 
Cooper J, Raeburn AL, Brumfitt W, and Hamilton -Miller JMT. General practitioner study: 
Fosfomycin trometamol versus amoxycillin clavulanate in acute urinary tract infections. 
Chemother 1990:36(suppl 1):24-26. 
Critchley IA, Cotroneo N, Pucci MJ, Mendes R (2019) The burden of antimicrobial resistance 
among urinary tract isolates of Escherichia coli in the [LOCATION_002] in 2017. PLoS ONE 14(12): 
e0220265. https://doi.org/10.1371/ journal.pone.0220265  
 Dunne MW, Aronin SI, Yu KC, Watts JA, and Gupta V.  A multicenter analysis of trends in 
resistance in urinary Enterobacterales isolates from ambulatory patients in the [LOCATION_002]: 2011- 2020. BMC Infect Dis 2022;22:194.  https://doi.org/10.1186/s12879-022-[ZIP_CODE]-y.  
 Dunne MW, Puttagunta S, Aronin SI, Brossette S, Murray J, Gupta V. Impact of empi[INVESTIGATOR_266496]. Microbiology Spectrum 2022;10(1):e02359-21. 
 
Edowik Y, Caspari T, Williams HM. The Amino Acid Changes T55A, A273P and R277C in the 
Beta-Lactamase CTX -M-[ADDRESS_324453] Infections. Microorganisms. 2020; 8(12).  
 
Foulds G, Knirsch A, Lazar J, et al. Pharmacokinetics of the penem CP 65,207 and its separate 
stereoisomers in humans. Antimicrob Agents Chemother 1991;35:[ADDRESS_324454] A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag  JJ. AAC 1993;37:1073-
1081. 
Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, Moran GJ, Nicolle LE, Raz R, 
Schaeffer AJ, Soper DE; Infectious Diseases Society of America; European Society for 
Microbiology and Infectious Diseases. International cl inical practice guidelines for the treatment 
of acute uncomplicated cystitis and pyelonephritis in women: A [ADDRESS_324455] Dis. 2011 Mar 1;52(5):e103- 20. doi: 10.1093/cid/ciq257. PMID: 21292654.   IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -[ADDRESS_324456] infections. Antimicrob Agents Chemother 1983;24(5):716-719. 
 
Hooten TM, Scholes D, Gupta K, Stapleton AE, Roberts PL, Stamm WE. Amoxicillin -
clavulanate vs ciprofloxacin for the treatment of uncomplicated cystitis in women. A randomized 
trial. JAMA 2005; 293:949-955.  
Hooton TM, Roberts PL, Stapleton AE. Cefpodoxime vs ciprofloxacin for short -course treatment 
of acute uncomplicated cystitis. A Randomized Trial. JAMA 2012;307:583-589. 
Huttner A, et al. Effect of [ADDRESS_324457] infection in women. JAMA. 2018;319(17):1781-1789. doi:10.1001/jama.2018.3627. 
 
Kaye KS, et al. Effect of Meropenem -Vaborbacta m vs Pi[INVESTIGATOR_049] -Tazobactam on Clinical Cure 
or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial. JAMA 2018;319(8):788- 799. doi: 
10.1001/jama.2018.0438. PMID: 29486041; PMCID: PMC5838656.  
 
Kaye KS, Gupta V, Mulgirigama A, Joshi AV, Scangarella -Oman NE, Yu K, Ye G, Mitrani -
Gold FS. Antimicrobial Resistance Trends in Urine Escherichia coli  Isolates From Adult and 
Adolescent Females in the [LOCATION_002] From 2011 to 2019: Rising ESBL Strains and Impact on 
Patient Management. Clin Infect Dis. 2021 Dec 6;73(11):1992- 1999. doi: 10.1093/cid/ciab560. 
PMID: 34143881; PMCID: PMC8664433.  
Lan KKG, and Wittes, J. The B -value: A tool for monitoring data. Biometrics 1988; 44: 579-585 
 Le VVH, Rakonjac J (2021) Nitrofurans: Revival of an ‚Äúold‚Äù drug class in the fight against 
antibiotic resistance. PLoS Pathog 17(7): e1009663.  https://doi.org/10.1371/journal. 
ppat.[ADDRESS_324458] Infections Caused by [CONTACT_266539] : The Role of Prior Exposure to Fluoroquinolones. Antibiotics 2021, 10, 
582. 
Mehta CR and Pocock SJ. Adaptive increase in sample size when interim results are promising: 
A practical guide with examples. Statist. Med. 2011, 30 3267‚Äì3284. 
Munoz- Davila MJ. Role of old antibiotics in the era of antibiotic resistance. Antibio tics 2014; 
3:39-48. National Institute for Health and Care Excellence. Urinary tract infection (lower): antimicrobial 
prescribing guideline. Evidence review for NICE Guideline. October 2018.  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 68 of 84  
Paterson DL. "Collateral damage" from cephalosporin or quinolone  antibiotic therapy. Clin 
Infect Dis 2004; 38(Suppl. 4):S341‚Äì5.  
Ramphal R, Ambrose PG. Extended- spectrum b -lactamases and clinical outcomes: current data. 
Clin Infect Dis 2006; 42(Suppl. 4):S164‚Äì72.  
 
Sanchez GV, Master RN, Karlowsky JA, Bordon JM. In vitr o antimicrobial resistance of urinary 
Escherichia coli isolates among U.S. outpatients from 2000 to 2010. Antimicrob Agents Chemother 2012; 56:2181‚Äì3.  
 
Schito GC, Naber KG, Botto H, Palou J, Mazzei T, Gualco L, Marchese A. The ARESC study: 
an international  survey on the antimicrobial resistance of pathogens involved in uncomplicated 
urinary tract infections. Int J Antimicrob Agents. 2009 Nov;34(5):407- 13. doi: 
10.1016/j.ijantimicag.2009.04.012. Epub 2009 Jun 7. PMID: 19505803.  
 
Thomas- White K, Forster SC, Kumar N, et al. Culturing of female bladder bacteria reveals an 
interconnected urogenital microbiota. Nature Communications 2018;9:1557 DOI: 
10.1038/s41467-018-[ZIP_CODE]-5. 
US Department of Health and Human Services.  Non-inferiority Clinical Trials to Establish 
Effectiveness.  Guidance for Industry.  Washington, DC:  US Food and Drug Administration; 
Clinical/Medical. November 2016.  
Wagenlehner FM, et al. Ceftazidime- avibactam Versus Doripenem  for the Treatment of 
Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 
Randomized Trial Program. Clinical Infectious Diseases 2016;63(6):754762; 
https://doi.org/10.1093/cid/ciw378.  
Wagenlehner FME, et al. Once- Daily Plazomicin for Complicated Urinary Tract Infections. N 
Engl J Med 2019;380:729- 40. DOI: 10.1056/NEJMoa1801467.  
 
Westfall PH, Krishen A. Optimally weighted, fixed sequence and ga tekeeper multiple testing 
procedures. Journal of Statistical Planning and Inference 2001; 99:25-40. 
Zhanel GG, et al. In vitro activity of sulopenem and comparative agents against bacterial 
pathogens isolated from Canadian patients with urinary tract infec tions: CANWARD 
surveillance study 2014- 2020. Poster presentation World Microbe Forum, June 2021.  
  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 69 of 84 APPENDIX 1     RATIONALE FOR AMOXICILLIN/CLAVULANATE AS 
COMPARATOR IN UNCOMPLICATED UTI TRIAL  
Amoxicillin/clavulanate is an oral antibacterial combination consisting of the semisynthetic 
antibiotic amoxicillin and the Œ≤ -lactamase inhibitor, clavulanate ( the potassium salt of clavulanic 
acid). The formulation of amoxicillin and clavulanic acid protects amoxicillin from degradation 
by Œ≤-lactamase enzymes and effectively extends the antibiotic spectrum of amoxicillin to include 
many bacteria normally resistant to amoxicillin and other Œ≤ -lactam antibiotics. 
Amoxicillin/clavulanate has activity against gram- positive and gram -negative aerobes and 
anaerobes, including the following Enterobacterales responsible for the majority of cases of uUTI: E. coli , Klebsiella species, and Proteus  mirabilis . FDA- approved indications for 
amoxicillin/clavulanate include treatment of urinary tract infections, lower respi[INVESTIGATOR_6014], otitis media, sinusitis, and skin and skin structure infections  [Augmentin USPI] . 
Amoxicillin/clavulanate is also approved in Europe for the treatment of UTI and is still the most prescribed antimicrobial (in 26.5% of the cases) to treat community -onset UTI  in some European 
countries [ Martinez- Casanova 2021].  
Amoxicillin/clavulanate  was chosen as the comparator for Study IT001-[ADDRESS_324459] infection [Augmentin USPI],  it is 
considered as a treatment option for acute uUTI in the IDSA Treatment Guideline [ Gupta 2011 ], 
and as a Œ≤ -lactam antibiotic, it is likely to have a similar effect to sulopenem on the female 
urogenital microbiome, thus allowing for a fair comparison of efficacy.  The dose of 
amoxicillin/clavulanate (875 mg/125 mg PO twice daily) was chosen to justify the use of amoxicillin/clavulanate CLSI breakpoints  for uncomplicated urinary tract infection ( M100 
Performance Standards for Antimicrobial Susceptibility Testing, 32
nd edition ).    
1. Per the approved label [Augmentin USPI], amoxicillin/clavulanate is an approved antibiotic 
for the indication of urinary t ract infection.  
‚ÄòIndication:  
Urinary Tract Infections ‚Äì caused by Œ≤ -lactamase‚Äìproducing strains of E. coli, 
Klebsiella spp., and Enterobacter spp.  
While AUGMENTIN is indicated only for the conditions listed above, infections caused by [CONTACT_266540][INVESTIGATOR_10312] -susceptible organisms are also amenable to treatment with AUGMENTIN 
due to its amoxicillin content; therefore, mixed infections caused by [CONTACT_266540][INVESTIGATOR_10312] -
susceptible organisms and Œ≤ -lactamase‚Äìproducing organisms susceptible to 
AUGMENTIN should not require the addition of another antibiotic.‚Äô  
 
‚ÄòDosage Adults: The usual adult dose is one [ADDRESS_324460], the dose should be one 875 -mg tablet of 
AUGMENTIN every 12 hours or one 500 -mg tablet of AUGMENTIN every 8 hours.‚Äô   
 Based on the Guidance for ‚ÄúNon- inferiority clinical trials to establish effectiveness‚Äù 
amoxicillin/clavulanate is therefore an approved agent to use as a comparator in a noninferiority 
trial for patients with urinary tract infection.  
2. Amoxicillin/clavulanate is listed as a treatment option in the IDSA Treatment Guidelines
 
[Gupta, 2011 ]. IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 70 of 84 ‚ÄòŒ≤-Lactam agents, including amoxicillin/clavulanate , cefdinir, Cefaclor, and 
cefpodoxime- proxetil, in 3 -7-day regimens are appropriate choices for therapy when 
other recommended agents cannot be used (B - 1). Other Œ≤-lactams, such as cephalexin, 
are less well  studied but may also be appropriate in certain settings (B -III).‚Äô  
It is important to understand that the IDSA Treatment Guidelines were last updated in 2010 
(published in 2011). At that time, the authors aimed to balance issues of in vitro  resistance and 
collateral damage (a term describing ecological adverse effects of  antimicrobial therapy, such as 
the selection of drug- resistant  organisms and colonization or infection with multidrug -resistant  
organisms ) when making their recommendations for optimal and alternative treatment options.  
At that time, rising rates of resistance to quinolones and trimethoprim- sulfamethoxazole (TMP -
SMX) had been shown for outpatient urinary isolates 2000-2010 [ Sanchez 2012], and increased 
collateral damage was found to be associated with broad -spectrum  cephalosporins and 
quinolones [ Paterson 2004; Ramphal 2006 ]. As shown in the Table below, pi[INVESTIGATOR_266497], a Œ≤ -
lactam, had the lowest estimated clinical and microbiological efficacy of all the optimal and 
alternativ e treatment agents in the IDSA Guideline, yet it was listed as an optimal choice given 
its low resistance rates and low propensity to cause collateral damage.  Other Œ≤ -lactams were 
listed as alternative agents, yet their estimated clinical and microbiologic efficacy was higher 
than pi[INVESTIGATOR_266498], both listed as optimal agents.  High 
resistance rates were noted for Œ≤ -lactams, specifically ampi[INVESTIGATOR_266499], and high 
propensity to cause collateral damage was noted, specif ically for broad- spectrum cephalosporins.  
Ciprofloxacin had one of the highest efficacy rates observed, an estimated clinical and 
microbiological efficacy of 90% and 91%, respectively, but was listed as an alternative agent due 
to rising resistance rates and its high propensity to cause collateral damage.   
  
 
 
 
 
 
 
 
 
 
 
 
 IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 71 of 84 Table 2 Comparison of Optimal and Alternative Treatment Regimens, IDSA Guidelines  
Antibiotic  / 
Class  
 
 Dose  Estimated 
clinical 
efficacy,  
Mean % 
(range)  Estimated 
microbiolo
gical 
efficacy  
Mean %, 
(range)  Efficacy 
Comments  Estimated  
E. coli  
Resistanc
e Rate, 
2011 Resistance 
Comments  Propensity to 
Cause Collateral 
Damage 
Optimal Treatment Options  
Nitrofurantoin  100 mg 
BID x 5 -7d 93 (84 -95) 88 (86-92) Efficacy 
comparable to 3 days of 
TMP -SMX  1.6-4.8%  Minimal 
resistance  Minimal propensity 
for collateral damage 
TMP -SMX  160/800 
mg BID x 3d 93 (90 -
100) 94 (91 -
100) Favorable 
efficacy as assessed in 
numerous 
clinical 
trials  24.2-
27.7% Appropriate 
choice if local 
resistance rates of uropathogens 
causing acute 
uncomplicated 
cystitis do not 
exceed 20%  Has been 
demonstrated to significantly affect 
the normal fecal 
flora, but generally 
not thought to have a 
propensity for 
collateral damage  
Fosfomycin  3 gm  single 
dose sachet  91 (NA)  80 (78 -83) Appears to 
have inferior 
efficacy 
compared 
with 
standard 
short-
course 
regimens  1.9% (ex -
US data)  Minimal 
resistance  Minimal propensity 
for collateral damage IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil  Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December  2022 
Confidential Page 72 of 84 Pi[INVESTIGATOR_266497]  400 mg 
BID x 3 -7d 73 (55 -82) 79 (74-84) May have 
inferior 
efficacy 
compared 
with other 
available 
therapi[INVESTIGATOR_014]  4.2% (ex -
US data)  Minimal 
resistance  Minimal propensity 
for collateral 
damage 
Alternative antimicrobial choices  
Quinolones  Dose varies 
by [CONTACT_119944]; 3-d 
regimen  90 (85 -98) 91 (81-98) Highly 
efficacious  17.1‚Äì26% Rising rates of 
resistance  Propensity for 
collateral damage 
Œ≤-lactams  Dose varies 
by [CONTACT_119944]; 3-5d 
regimen  89 (79 -98) 82 (74 -98) Generally, 
have 
inferior 
efficacy  43.4-
50.3% High rates of 
resistance for 
ampi[INVESTIGATOR_266500]- spectrum 
cephalosporins to cause collateral 
damage  
Source: Schito 2009; Gupta 2011; Sanchez 2012; Kaye 2021; Dunne 2022  
 IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil   Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -[ADDRESS_324461] the empi[INVESTIGATOR_266501] -SMX for 
acute cystitis if local resistance rates of uropathogens causing acute uncomplicated cystitis 
exceeded 20%. Due to the resistance rates at the time, a similar recommend ation was not 
made for other agents, but it has since become a common clinical practice to apply this 20% threshold to local resistance data in order to guide empi[INVESTIGATOR_266502].   
 Since the [ADDRESS_324462] exceeded or 
approached the 20% threshold for quinolones and nitrofurantoin, respectively. For  
nitrofurantoin, resistance to E. coli  is approximately 4%, but nitrofurantoin resistance rates 
for Enterobacterales  other than E. coli  are markedly elevated (88 -100% for Proteus mirabilis , 
58-63.0% for Klebsiella  pneumoniae , and approximately 57% for all other Enterobacterales) 
making the empi[INVESTIGATOR_266503] [ Huttner 2018, Zhanel  2021, Dunne 
2022].  
 Rising nitrofurantoin resistance rates are likely a direct consequence of increased 
nitrofurantoin utilization in response to high TMP -SMX and quinolone  resistance rates.  In 
one [LOCATION_008] location, the authors believe that incre ased exposure of E. coli  to 
nitrofurantoin resulted in the emergence of a mutated version of the ESBL CTX -M-14 
enzyme. When this mutated CTX -M-14 enzyme was recombinantly overexpressed in a 
laboratory strain of E. coli , a strain emerged that was hyper -resistant to nitrofurantoin while 
retaining Œ≤ -lactam resistance [Edowik 2021].  Given that globally CTX -M-14 is one of the 
predominant ESBL types  [Banerjee 2014 ], over time  with continued E. coli  exposure to 
nitrofurantoin , select ion for this nitrofurantoin -resistant mutant is likely [ Le 2021].   
 To add to the complexity, there has been a rapid increase in both the rate of ESBL -producing 
pathogens, and the rate of co- resistance to two or more standard agents [ Critchley 2019, 
Kaye 2021, Dunne 2022 ].   
 Resistanc e rates for amoxicillin/clavulanate are not provided in the IDSA Guidelines.  As 
shown in Table 3 below, based on the results of Study IT001- 301, the expected rate of 
resistance to amoxicillin/clavulanate is less than to quinolones and TMP -SMX, and 
comparable to nitrofurantoin. These findings, in conjunction with what is known about clinical response, microbiologic response, and propensity to cause collateral damage for 
uUTI patients treated with amoxicillin/clavulanate, support the use of amoxicillin/clavulanate 
as a safe and effective comparator in a non -inferiority uUTI trial.  
  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil   Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December 2022 
 
Confidential Page 74 of 84  
Table 3   Resistance Rate for Baseline Pathogen(s), IT001-301  
Antibiotic/Class  Resistance Rate  
n (%)  
N=1071  
Amoxicillin/clavulanate  205 (19.1)  
Nitrofurantoin  192 (17.9)  
Trimethoprim- sulfamethoxazole  338 (31.6)  
Ciprofloxacin  293 (27.4)  
Source: IT001 -301 CSR; posthoc Table 198  
 
While amoxicillin/clavulanate is listed as a treatment option in the 2011 IDSA Guidelines , 
and the document provides useful historical information to help guide the management of 
patients with suspected and confirm ed acute uncomplicated cystitis, the  Guidelines are 
outdated, not based on efficacy alone,  and cannot be relied upon  to steer  the choice of a 
comparator agent for a non- inferiority trial in uUTI in 2022.     
 A more recent antimicrobial prescribing guideline for lower UTI from the National Institute 
for Health and Care Excellence published in October 2018 indicates that the efficacy of Œ≤ -
lactams is not significantly different than that compared to nitrofurantoin, trimethoprim -
sulfamethoxa zole or quinolones based on a large meta -analysis of randomized controlled 
trials [ NICE Guideline 2018].  
 
3. Availability of data regarding the degree of asymptomatic bacteriuria:  
 In Study IT001- 301, sulopenem was not non -inferior to ciprofloxacin in patients whose 
baseline uropathogen was susceptible to ciprofloxacin.  The difference in response rates was driven almost exclusively by a greater proportion of asymptomatic patients with the baseline 
uropathogen isolated at the test of cure visit in patients who received sulopenem. The 
presence of asymptomatic bacteriuria a week or more after completing therapy was not 
associated with a higher rate of clinical relapse, making it likely that the presence of 
pathogens in the urine culture was not a reflection of  incomplete eradication of the offending 
baseline organism and more likely due to recolonization of the bladder.   
A possible explanation why asymptomatic bacteriuria would occur sooner post -treatment for 
patients receiving sulopenem than for those receiving ciprofloxacin is that ciprofloxacin has a more significant impact on the vaginal flora than a Œ≤-lactam such as sulopenem, and that this 
effect on the vaginal flora affects the rate at which women recolonize the bladder. Similar observations have been made in two previous studies of the treatment of uncomplicated 
urinary tract infection and recently in a mouse model of urinary tract infection [ Hooton 2005, 
Hooton 2012, Brannon 2020]. The area under the curve (AUC) of ciprofloxacin in plasma over 24 hours after a 250 mg bid dose is approximately 9.6 Œºg ‚Ä¢ h/mL [Cipro USPI]. An 
AUC
24/MIC of approximately 125 is the ratio required for achieving clinical and 
microbiologic success with ciprofloxacin [ Forrest 1993] and this ratio would be achieved for IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil   Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December 2022 
 
Confidential Page 75 of 84 organisms with an MIC of <0.06 ¬µ g/mL. Consistent with this potential effect, and assuming 
tissue concentrations are equal to plasma, a lower rate of asymptomatic bacteriuria was only 
seen in those ciprofloxacin- treated patients whose baseline uropathogen had an MIC of <0.06 
mg/mL. This effect would be relevant not for organisms residing in the urine as the urine concentrations of ciprofloxacin are significantly higher than plasma, but rather for those 
organisms in the colonizing flora of the perineum and vaginal mucos a, a potential source of 
organisms for recolonization of the bladder [ Thomas- White 2018, Brannon 2020 ].  
 
This concentration dependent effect of ciprofloxacin on the vaginal flora would also carry 
with it the potential for selection of increasingly more re sistant pathogens in the post -
treatment flora. In Study IT001- 301, 35/415 (8.4%) patients without culture evidence of a 
ciprofloxacin resistant pathogen at baseline had a ciprofloxacin resistant pathogen in their 
urine culture post -treatment. More worrisome was that many of these ciprofloxacin resistant 
isolates also carried the blaCTX -M-15 extended spectrum Œ≤ -lactamase resistance gene, a 
commonly circulating plasmid among E. coli  [Banerjee 2014], making treatment in the future 
with either a quinolone or a Œ≤ -lactam other than a penem less likely to be successful.  
 
While the antibiotic effect on a woman‚Äôs vaginal flora, and subsequently the rate of bladder 
recolonization, is likely a class effect, other host factors and mechanisms may be at play, and 
the association between specific antibiotics and post -treatment asy mptomatic bacteriuria is 
not known. This makes it challenging to confidently choose a comparator in a noninferiority trail, as long as microbiologic outcome remains part of the primary endpoint.  It is reasonable 
to assume that a Œ≤ -lactam comparator such as amoxicillin/clavulanate will have a similar 
effect to sulopenem on the urogenital microbiome, thus allowing for a fair comparison of efficacy.  Additional data from Study IT001- 302 supports using amoxicillin/clavulanate as 
the comparator.  As shown in  Table 4 below, in Study IT001- 302, a higher incidence of 
asymptomatic bacteriuria was observed in complicated UTI patients receiving sulopenem.  
This difference in the proportion of patients with asymptomatic bacteriuria was observed primarily among the patients who had ciprofloxacin- susceptible uropathogens and, per 
protocol, received ciprofloxacin as step -down treatment.  Of the patients who received IV 
sulopenem and stepped down to oral sulopenem, 21.8% failed due to asymptomatic 
bacteriuria at TOC compared to just 4.7% of those who received IV ertapenem and stepped 
down to oral ciprofloxacin.  Of the patients with ciprofloxacin- nonsusceptible uropathogens, 
those in the ertapenem group, depending on their clinical status, either received their entire 
treatment course IV or were stepped down to amoxicillin/ clavulanate.  The rate of 
asymptomatic bacteriuria as the reason for failure among these patients was similar to that of sulopenem patients, supporting the use of amoxicillin/clavulanate as the comparator in our 
planned uncomplicated UTI noninferiority trial.  
 
 
 
 
 
 IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil   Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December 2022 
 
Confidential Page 76 of 84  
Table 4   Overall Response at TOC by [CONTACT_266511], IT001- 302, m icro-MITT 
Population  
Outcome Sulopenem  
n (%) Ertapenem 
n (%)  Difference (%), 
(95% CI)  
All patients  
Primary Endpoint:  Overall Success 
(TOC) 301/444 (67.8)  325/440 (73.9)  -6.1 ( -12.0, -0.1)  
Reason for failure:  Asymptomatic 
bacteriuria 93 (20.9)  59 (13.4)   
Patients with ciprofloxacin susceptible isolates by [CONTACT_266541] / oral Sulopenem  
 n (%)  Ertapenem IV / oral ciprofloxacin n (%)   
Overall Success  168/248 (67.7)  186/215 (86.5)  -18.8 (-26.1, -
11.0) 
Reason for failure:  Asymptomatic bacteriuria 54 (21.8)  10 (4.7)   
 Sulopenem IV  Ertapenem IV (n=26) 
or 
Ertapenem IV / oral 
Amoxicillin/clavulanate 
(n=6)  
Overall Success  19/34 (55.9)  17/32 (53.1)  2.8 (-20.9, 26.2)  
Reason for failure:  Asymptomatic bacteriuria 7 (20.6)  7 (21.9)   
Patients with ciprofloxacin non -susceptible isolates by [CONTACT_266542] / Sulopenem -
Etzadroxil + 
Probenecid 
n (%)  Ertapenem IV only or 
Ertapenem IV / 
Amoxicillin/clavulanate  
n (%)   
Overall Success  114/162 (70.4)  122/193 (63.2)  7.2 (-2.7, 16.8)  
Reason for failure:  Asymptomatic bacteriuria 32 (19.8)  42 (21.8)   
Source: IT001-[ADDRESS_324463] that efficacy rates for sulopenem in IT001 -302 are consistent with 
those seen for other IV penems in recent cUTI trials where step -down to an oral agent was 
not allowed [ Wagenlehner 2016, Kaye 2018, Wagenlehner 2019]. These approved penems 
have proven to be effective life -saving drugs.  
 In conclusion, amoxicillin/clavulanate is an appropriate comparator for our proposed non-
inferiority trial in patients with uUTI. It is an FDA -approved agent for the treatment of UTI, IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil   Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -[ADDRESS_324464] on the female 
urogenital microbiome.  Amoxicillin/clavulanate breakpoints as per CLSI (M100 
Performance Standards for Antimicrobial Susceptibility Testing, 32nd edition). 
 
REFERENCES:  
See Reference List in Section 16 above. 
 
   
  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil   Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December 2022 
 
Confidential Page 78 of 84 APPENDIX 2  SCHEDULE OF STUDY ASSESSMENTS 
 SCREENING  TREATMENT PERIOD  FOLLOW -UP PERIOD   
Protocol Activity  D-1 to D1  
 
Baseline  D13 D5 
(+ 1 day)  
EOT D12 
(¬± 1 day)  
TOC D28 
(¬± 2 days)  
FV Premature Study 
Discontinuation  
Informed Consent  X      
Medical History and 
Demographics X      
Targeted Physical 
Examination X  X1 X1 X1 X1 
Vital Signs  X  X X  X 
Hematology  X   X  X 
Serum Chemistry  X   X  X 
Pregnancy testing2 X    X X 
Banked serum sample  X   X   
Banked urine sample  X  X X   
Urinalysis  X  X X X X 
Urine Culture and 
sensitivity  X  X X X X 
Previous Drug and 
Non-drug Treatments  X      
Concomitant 
Medications  X X X X X 
Provide daily dosing 
diary   X     
Collect daily dosing 
diary    X   X 
Study Drug 
Treatment   X  (BID x 10 doses total )    
Study Drug 
Compliance Check    X   X 
Adverse Events  X X X X X X 
Patient Symptom 
Assessment 
Questionnaire 
(PSAQ)   X X X X X 
Investigator 
Assessment of 
Clinical Response   
 X X X X 
 
Schedule of Activities Footnotes:  
1 If needed, based on symptoms, as determined by [CONTACT_093]  
2 Baseline and Day 28 (¬±2 days)  or Premature  Discontinuation: Pregnancy test (women of childbearing potential and peri -menopausal women, defined 
as women < 50 years of age or those ‚â• [ADDRESS_324465] -menopausal for < 2 years) should be performed as required by [CONTACT_12695]  
3 Day 1 and Screening are generally on the same day  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil   Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December 2022 
 
Confidential Page 79 of 84 APPENDIX 3  MICROBIOLOGY  
Method of Collection of Urine Specimens:  
To obtain a clean catch sample of urine from a female patient  and avoid specimen 
contamination , a thorough cleansing of the periurethral area is essential before specimen 
collection. Clean the area with a disinfectant and  make all efforts to avoid any contact [CONTACT_266543]. Urine samples should be collected by [CONTACT_222304]- catch midstream . Details 
of appropriate methodology for urine sample collection, handling, and storage  will be 
provided in the laboratory manual.  
All patients should void the first part of the specimen into the toilet, then collect the 
remainder of the specimen in a sterile  container. Urine samples for routine culture must be 
transported in the urine transport tubes provided by [CONTACT_1034].  
If feasible, urine specimens  should be collected [ADDRESS_324466] void. 
Culture and Susceptibility testing  
All gram -negative path ogens and S. saprophyticus  will be tested by [CONTACT_266544].  
The Central laboratory should retain all isolates until the end of the study, if possible. 
Additional samples for culture may  be requested if the Central laboratory does not receive a 
viable culture.  
Susceptibility results of pathogens to amoxicillin /clavulanate and carbapenems from cultures 
obtained at Screening, EOT, and TOC should not be reported to sites/investigators until after 
the TOC visit, unless requested by [CONTACT_079] [INVESTIGATOR_266493], so as 
not to influence the investigator‚Äôs decision to prescribe a rescue antibiotic in the case of presence of a non -susceptible pathogen.  
Organisms considered as pathogens  
For the purpose of this study protocol, the following organisms will always be considered a 
pathogen when isolated from an acceptable urine culture specimen:  
‚Ä¢ Monomicrobial or polymicrobial infections caused by:  
‚Ä¢ Enterobacterales  
‚Ä¢ Enterococci  
‚Ä¢ Pseudomonas aeruginosa  
‚Ä¢ S. saprophyticus  
The micro -MITT population for this study will only include patients with uUTI 
caused by [CONTACT_266545]/or S. saprophyticus . 
‚Ä¢ Even if the organism was isolated from an acceptable urine culture specimen, the 
following are never a pathogen  for this study: 
‚Ä¢ Corynebacterium  spp. 
‚Ä¢ S. epi[INVESTIGATOR_77353]  
‚Ä¢ S. aureus  
‚Ä¢ Bacillus spp. 
‚Ä¢ Diphtheroids IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil   Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December 2022 
 
Confidential Page 80 of 84 ‚Ä¢ Micrococcus  spp. 
‚Ä¢ Lactobacillus  spp. 
‚Ä¢ Viridans Streptococci  
‚Ä¢ Group B Streptococci  
‚Ä¢ Gardnerella vaginalis  
‚Ä¢ Neisseria gonorrhoeae  
‚Ä¢ Yeasts  
‚Ä¢ A study urine culture positive for more than [ADDRESS_324467] 
in determining if the isolate is a pathogen.  
Based on the results of in vitro testing, animal studies, PK/PD modeling, surveillance programs and clinical trial data, a provisional breakpoint for susceptibility of sulopenem to 
Enterobacterales , Streptococci and methicillin -susceptible Staphylococcus aureus  is ‚â§ 0.5 
¬µg/mL. Tentative d isc diffusion interpret ive criteria are available for sulopenem. A detailed 
description of the relevant microbiology data is available in the investigator brochure.  
 
 
  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil   Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December 2022 
 
Confidential Page 81 of 84  
APPENDIX 4 CRITERIA FOR SAFETY LABORATORY VALUES 
OF POTENTIAL CLINICAL CONCERN 
Hematology   
Hemoglobin  <0.8 times the lower limit of the reference range  
Leukocytes  <1.5 or > 20 x 103/mm3 
Platelets  
 <75 or >700 x 103/mm3 
   
Chemistry   
Total bilirubin  >[ADDRESS_324468]  bilirubin >[ADDRESS_324469]  >3 times upper limit of the reference range  
ALT  >3 times upper limit of the reference range  
GGT  >3 times upper limit of the reference range  
Alkaline  phosphatase >3 times upper limit of the reference range  
Creatinine  >1.5 times upper limit of the reference range  
BUN/Urea  >1.3 times upper limit of the reference range  
Sodium <0.95 or >1.05 times the limits of the reference range  
Potassium  <0.9 or >1.1 times the limits of the reference range  
  
Albumin <0.8 times the lower limit of the reference range  
 
  
Urinalysis   
Urine WBC  ‚â•10/HPF  
Urine RBC  ‚â•50/HPF  
  
Vital Signs   
Pulse Rate  <40 or >1 30 bpm , when baseline resting heart rate is 60 -120 bpm  
Blood Pressure  Systolic ‚â•30 mm Hg change from baseline in same posture  
 Systolic < 80 mm Hg  
 Diastolic ‚â•20 mm Hg change from baseline in same posture  
 Diastolic <50 mm Hg  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil   Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -[ADDRESS_324470] been made for ease of reading, formatting, spelling, 
grammar, and consistency are not included in this summary of changes.  
 
Section  Change  
Study Population 
Selection ( Section 4,  
page 35)  Female patients who present with uUTI, defined by [CONTACT_266546] a urinalysis 
suggestive of a uUTI per Section 4.1 positive for pyuria , and who meet all of the 
inclusion and none of the exclusion criteria will be eligible for participation in this study.  
Rationale: To align with changes made to Section 4.1 below.  
Inclusion Criteria 
(Synopsis and S ecti on 
4.1, page 35) 1. Female patients ‚â•18  years of age with ‚â•24 hours and ‚â§96 hours of 
urinary symptoms attributable to a UTI  
2. Two of the following signs and symptoms of uUTI: urinary frequency, 
urinary urgency, pain or burning on micturition, suprapubic pain  
3. A mid -stream urine specimen with:  
a. a machine-read dipstick positive for nitrite AND any positive 
leukocyte est erase  
OR 
b. evidence of pyuria alone as defined by [CONTACT_5640]:  
i. a machine-read dipstick positive for large leukocyte 
esterase OR  
ii. at least 10 white blood cells per cubic millimeter on 
microscopic analysis of unspun urine OR  
iii. White blood cell count ‚â•10 cells/HPF in the sediment 
of a spun urine  
4. Has given written informed consent to participate in the study  
Rationale: To optimize enrol lment of patients with the disease under study and 
to increase successful collection of a positive urine culture  for >100,000 
CFU/mL of a uropathogen.  
Women of Child -
Bearing Potential 
(Sect
ion 4.5 , page 38) She must agree to continue all of these contraceptive methods until the last 
Study Visit. Within these limits, the specific forms of contraception employed are left to the discretion of the patient, and/or the principal investigator, and/or the patient‚Äôs physician and documented in source.  
Rationale:  To improve clarity regarding site documentation of forms of 
contraception for women of child -bearing potential.  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil   Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December 2022 
 
Confidential Page 83 of 84 Administration 
(Synopsis and Section 
5.2.3, page 39)  Patients randomized to the sulopenem treatm ent group will take one sulopenem 
etzadroxil/probenecid tablet and one placebo capsule twice daily for 5 days and 
those randomized to the amoxicillin/clavulanate treatment group will take one over- encapsulated amoxicillin/clavulanate tablet and one placebo  tablet twice 
daily for 5 days  (10 doses total over a 5-day period; if Dose 1 is taken in the 
evening of Day 1, Dose 10 will be taken in the morning of Day 6). The first dose 
of each medication will be administered under the supervision of study site personnel to help ensure compliance with dosing directions.  
Study drug administration will be documented in accordance with the Pharmacy Manual.  
Rationale: To improve clarity regarding administration of study medications.  
Appendix 2 (page 7 8) Study Drug Treatment         X (BID x 10 doses total for 5 days ) 
Rationale: To improve clarity regarding administration of study medications.  
 
3Day 1 and Screening are generally on the same day.  
Rationale: To improve clarity regarding timing of Day 1 in relation to Screening 
activities . 
Appendix 4 (page 8 1) Calcium                             <0.9 or >1.1 times the limits of the reference range   
Rationale: To clarify list of safety laboratory tests being performed.  
 
  IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024
Sulopenem etzadroxil   Iterum Therapeutics International Limited  
Clinical Trial Protocol: IT001 -310  December 2022 
 
Confidential Page 84 of 84 APPENDIX 6 INVESTIGATOR‚ÄôS SIGNATURE  
[CONTACT_2759]:  A prospective, Phase 3, randomized, multi -center, double -blind  
study of the efficacy, tolerability , and safety of oral sulopenem 
etzadroxil/ probenecid versus oral amoxicillin/clavulanate  for 
treatment of uncomplicated urinary tract infections (uUTI) in adult 
women.  
Study Number:  IT001 -310 
Final Date:  
 
Amendment 1 
Date:  July 7, [ADDRESS_324471] the study according to the procedures therein and according to the principles of good clinical practice.  
 
 
Name:     
    
    
[INVESTIGATOR_7496]:   Date:   IT001-310 Protocol Amendment 1 12-5-2022 | VV-TMF-165994 | 1.0
Approved
Downloaded by [CONTACT_266506] 4/16/2024